

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007743 A2

(51) International Patent Classification⁷: C12Q (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(21) International Application Number: PCT/IB2003/003727 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 17 July 2003 (17.07.2003)

(25) Filing Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data: 60/396,432 17 July 2002 (17.07.2002) US

(71) Applicant: COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WAGNER, Hermann [DE/DE]; Kaagangerstrasse 36, 82279 Eching (DE). KRETZSCHMAR, Hans [DE/DE]; Nelkenweg 5a, 82515 Wolfratshausen (DE). SETHI, Shneh [DE/DE]; Platanen Strasse 56, 81377 Muenchen (DE).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/007743 A2

(54) Title: USE OF CPG NUCLEIC ACIDS IN PRION-DISEASE

(57) Abstract: Methods are provided which are useful in the treatment of prion diseases and other protein deposit diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids, including CpG nucleic acids.

- 1 -

USE OF CpG NUCLEIC ACIDS IN PRION DISEASE

Field of the Invention

The instant invention pertains to methods useful in the treatment of prion diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids.

Background of the Invention

Prion diseases include a number of fatal, neurodegenerative diseases believed to be caused by aggregates of normal protein that is present in an abnormal conformation. The normal protein, prion protein, is usually present in the cell membrane of many tissues, particularly neuronal tissue. The abnormally conformed prion protein is believed to be directly involved in converting normally conformed prion protein into more of the abnormally conformed prion protein, which then self-assembles into aggregates that are damaging to neuronal tissue anatomy and function.

At least some of the prion diseases are transmissible. However, unlike bacteria, viruses, fungi, parasites, and other replicating pathogens, transmissible prions are simply proteins; they are transmissible without any accompanying nucleic acid. For reasons that are not yet fully understood, the abnormally conformed prion proteins normally do not induce an immune response. Thus, exposure of a healthy individual to abnormally conformed prion protein can initiate a prion disease that can go unchecked by the immune system.

Exposure to abnormally conformed prion protein thus represents a health risk to susceptible individuals. Such individuals include humans and non-humans, principally cows and sheep. Exposure can come about through contact with prion-diseased animal products through ingestion, iatrogenic or work-related exposure, transplantation, and administration of pharmaceutical preparations.

Summary of the Invention

The instant invention is based in part on the unexpected discovery by the inventors that administration of immunostimulatory nucleic acid to a subject that is exposed to abnormally conformed prion protein is an effective treatment of prion disease. The immunostimulatory nucleic acid effectively delayed and even prevented disease in animals

- 2 -

administered very large doses of prion-diseased brain homogenates that uniformly caused fatal disease in all untreated control animals similarly exposed to prion-diseased brain homogenates.

The immunostimulatory nucleic acids are useful in the treatment of prion diseases, including Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), and scrapie. The methods of the invention are also useful for the study of these diseases, for instance, in animal models. The methods will also be useful for developing an understanding of how prion proteins normally fail to elicit an immune response and how an immune response can be elicited and used to treat prion protein disease.

The immunostimulatory nucleic acids are also useful in the treatment of other neurologic diseases involving abnormal protein deposits or aggregates. Such diseases include Alzheimer's disease, which involves deposits of amyloid. The main component of amyloid plaques is amyloid- β peptide (A β), a fibrillar 40-42 amino acid peptide that accumulates extracellularly and causes neuronal death.

In one aspect the invention provides a method for treating a prion disease in a subject. The method involves administering to a subject having or at risk of developing a prion disease a CpG nucleic acid in an effective amount to treat the prion disease. In one embodiment the administering follows exposure of the subject to a prion protein that is associated with a prion disease. In one embodiment the prion disease is a transmissible spongiform encephalopathy (TSE). In one embodiment the subject is a human.

In various preferred embodiments, the prion disease is scrapie, BSE, or a form of CJD. The CJD in one embodiment is iatrogenic CJD (iCJD). In another embodiment the CJD is variant CJD (vCJD). In yet another embodiment the CJD is sporadic CJD.

In one aspect the invention provides a method for inducing an immune response to a prion protein. The method according to this aspect of the invention involves the steps of contacting an antigen-presenting cell (APC) with a prion protein and contacting the APC with a CpG nucleic acid in an effective amount to induce an immune response to the prion protein. In one embodiment the immune response occurs *in vivo*. In one embodiment the immune response occurs *in vitro*. In all embodiments according to this aspect of the invention the APC is preferably chosen from a B cell, a dendritic cell, a macrophage, and a monocyte. In one preferred embodiment the APC is a dendritic cell.

- 3 -

Also according to this aspect of the invention, in one embodiment the APC expresses a Toll-like receptor (TLR) that signals in response to the CpG nucleic acid. It has recently been reported that CpG nucleic acid can specifically induce a particular TLR, designated TLR9, to signal. Accordingly, in one embodiment the TLR is TLR9.

In one embodiment the prion protein includes prion protein:scrapie form (PrP^{Sc}). In another embodiment the prion protein includes a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}. In yet another embodiment the prion protein includes a derivative of PrP^{Sc} or a derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}.

In one embodiment the prion protein is prion protein:scrapie form (PrP^{Sc}). In another embodiment the prion protein is a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}. In yet another embodiment the prion protein is a derivative of PrP^{Sc} or a derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}.

It has been reported that certain CpG nucleic acids are more effective in one species than in another. Accordingly, in preferred embodiments the CpG nucleic acid is optimized for use in a species of the subject.

It has also been reported that CpG nucleic acids appear to fall into different classes based on certain structural features as well as their function. At least three classes are believed to exist, denoted Class A, Class B, and Class C. In one embodiment the CpG nucleic acid is a class B CpG nucleic acid. In one embodiment the CpG nucleic acid is a class A CpG nucleic acid. In one embodiment the CpG nucleic acid is a class C CpG nucleic acid.

These and other features of the invention are described in greater detail in connection with the detailed description of the invention.

Detailed Description of the Invention

A major step in the study of prions and the diseases that they cause was the discovery and purification of a protein designated prion protein (PrP). Bolton et al. (1982) *Science* 218:1309-11; Prusiner SB et al. (1982) *Biochemistry* 21:6942-50; McKinley MP et al. (1983) *Cell* 35:57-62. Complete prion protein-encoding genes have since been cloned, sequenced and expressed in transgenic animals. PrP^C is encoded by a single-copy host gene (Basler K et

- 4 -

al. (1986) *Cell* 46:417-28) and is normally found at the outer surface of neurons. Prion diseases are accompanied by the conversion of PrP^C into a modified form called PrP^{Sc}.

The scrapie isoform of the prion protein (PrP^{Sc}) is thought necessary for both the transmission and pathogenesis of the transmissible neurodegenerative diseases of animals and humans. See Prusiner SB (1991) *Science* 252:1515-22. The most common prion diseases of animals are scrapie of sheep and goats and bovine spongiform encephalopathy (BSE; "mad cow disease") of cattle. Wilesmith J et al. (1991) *Microbiol Immunol* 172:21-38. Four prion diseases of humans have been identified: (1) kuru, (2) Creutzfeldt-Jakob disease (CJD), (3) Gerstmann-Sträussler-Scheinker (GSS) syndrome, and (4) fatal familial insomnia. Gajdusek DC (1977) *Science* 197:943-60; Medori et al. (1992) *N Engl J Med* 326:444-9.

Most CJD cases are sporadic, but about 10-15% are inherited as autosomal dominant disorders that are caused by mutations in the human PrP gene. Hsiao et al. (1990) *Neurology* 40:1820-7; Goldfarb et al. (1992) *Science* 258:806-8. Iatrogenic CJD has been caused by human growth hormone derived from cadaveric pituitaries as well as dura mater grafts. Brown et al. (1992) *Lancet* 340:24-7. Despite numerous attempts to link CJD to an infectious source such as the consumption of meat from scrapie-infected sheep, none has been identified to date (Harries-Jones et al. (1988) *J Neurol Neurosurg Psychiatry* 51:1113-9) except in cases of iatrogenically induced disease. On the other hand, kuru, which for many decades devastated the Fore and neighboring tribes of the New Guinea highlands, is believed to have been spread by infection during ritualistic cannibalism.

The major component of purified infectious prions, designated PrP 27-30, is the proteinase K resistant core of a larger native protein PrP^{Sc} which is the disease causing form of the ubiquitous cellular protein PrP^C. PrP^{Sc} is found only in scrapie infected cells, whereas PrP^C is present in both infected and uninfected cells implicating PrP^{Sc} as the major, if not the sole, component of infectious prion particles. Since both PrP^C and PrP^{Sc} are encoded by the same single copy gene, great effort has been directed toward unraveling the mechanism by which PrP^{Sc} is derived from PrP^C. Central to this goal has been the characterization of physical and chemical differences between these two molecules. Properties distinguishing PrP^{Sc} from PrP^C include low solubility (Meyer RK et al. (1986) *Proc Natl Acad Sci USA* 83:2310-4), poor antigenicity (Kascak RJ et al. (1987) *J Virol* 61:3688-93; Serban D et al. (1990) *Neurology* 40:110-7), protease resistance (Oesch B et al. (1985) *Cell* 40:735-46), and polymerization of PrP 27-30 into rod-shaped aggregates which are very similar, on the

- 5 -

ultrastructural and histochemical levels, to the PrP amyloid plaques seen in scrapie-diseased brains (Prusiner SB et al. (1983) *Cell* 35(2 Pt 1):349-58). By using proteinase K it is possible to denature PrP^C but not PrP^{Sc}. To date, attempts to identify any post-translational chemical modifications in PrP^C that lead to its conversion to PrP^{Sc} have proven fruitless. Stahl N et al. (1993) *Biochemistry* 31:5043-53. Consequently, it has been proposed that PrP^C and PrP^{Sc} are in fact conformational isomers of the same molecule.

Conformational description of PrP using conventional techniques has been hindered by problems of solubility and the difficulty in producing sufficient quantities of pure protein. However, PrP^C and PrP^{Sc} are conformationally distinct. Theoretical calculations based upon the amino acid sequences of PrPs from several species have predicted four putative helical motifs in the molecule. Experimental spectroscopic data would indicate that in PrP^C these regions adopt alpha-helical arrangements, with virtually no beta-sheet. Pan et al. (1993) *Proc Natl Acad Sci USA* 90:10962-6). In dramatic contrast, in the same study it was found that PrP^{Sc} and PrP 27-30 possess significant beta-sheet content, which is typical of amyloid proteins. Moreover, studies with extended synthetic peptides, corresponding to PrP amino acid residues 90-145, have demonstrated that these truncated molecules may be converted to either alpha-helical or beta-sheet structures by altering their solution conditions. The transition of PrP^C to PrP^{Sc} requires the adoption of beta-sheet structure by regions that were previously alpha-helical.

In general, scrapie infection fails to produce an immune response, with host organisms being tolerant to PrP^{Sc} from the same species. Polyclonal anti-PrP antibodies have been raised in rabbits following immunization with large amounts of Syrian hamster PrP 27-30. Bendheim PE et al. (1985) *Proc Natl Acad Sci USA* 82:997-1001; Bode L et al. (1985) *J Gen Virol* 66:2471-8. Similarly, a handful of anti-PrP monoclonal antibodies have been produced in mice. Kacsak RJ et al. (1987) *J Virol* 61:3688-93; Barry RA et al. (1986) *J Infect Dis* 154:518-21. These antibodies are able to recognize native PrP^C and denatured PrP^{Sc} from both Syrian hamsters and humans equally well, but do not bind to murine PrP. Unsurprisingly, the epitopes of these antibodies were mapped to regions of sequence containing amino acid differences between Syrian hamster and murine PrP. Rogers et al. (1991) *J Immunol* 147:3568-74.

The DNA sequence of the human, sheep and cow PrP genes have been determined, allowing, in each case, the prediction of the complete amino acid sequence of their respective

- 6 -

PrP proteins. The normal amino acid sequence which occurs in the vast majority of individuals is referred to as the wild-type PrP sequence. This wild-type sequence is subject to certain characteristic polymorphic variations. In the case of human PrP, two polymorphic amino acids occur at residues 129 (Met/Val) and 219 (Glu/Lys). Sheep PrP has two amino acid polymorphisms at residues 136 and 171, while bovine PrP has either five or six repeats of an eight amino acid motif sequence (octarepeats) in the amino terminal region of the mature prion protein. While none of these polymorphisms are of themselves pathogenic, they appear to influence prion diseases. Distinct from these normal variations of the wild-type PrP proteins, certain mutations of the human PrP gene which alter either specific amino acid residues of PrP or the number of octarepeats have been identified which segregate with inherited human prion diseases.

For example, sequences of chicken, bovine, sheep, rat, and mouse PrP genes are disclosed and published within Gabriel JM et al. (1992) *Proc Natl Acad Sci USA* 89:9097-101. A sequence for a PrP gene of Syrian hamster is published in Basler K et al. (1986) *Cell* 46:417-28. A PrP gene of sheep is published by Goldmann W et al. (1990) *Proc Natl Acad Sci USA* 87:2476-80. A gene sequence for bovine PrP is published in Goldmann W et al. (1991) *J Gen Virol* 72:201-4. A sequence for chicken PrP gene is published in Harris DA et al. (1991) *Proc Natl Acad Sci USA* 88:7664-8. A PrP gene sequence for mink is published in Kretzschmar HA et al. (1992) *J Gen Virol* 73:2757-61. A human PrP gene sequence is published in Kretzschmar HA et al. (1986) *DNA* 5:315-24. A PrP gene sequence for mouse is published in Locht C et al. (1986) *Proc Natl Acad Sci USA* 83:6372-6. A PrP gene sequence for sheep is published in Westaway D et al. (1994) *Genes Dev* 8:959-69. These publications are all incorporated herein by reference to disclose and describe the PrP gene and PrP amino acid sequences.

Human PrP cDNA (SEQ ID NO:1; GenBank Accession No. M13899)

cggcgccg	agttctcct	ctcctcacga	ccgaggcaga	gcagtcatta	tggcgaacct	60
tggctgtgg	atgctggttc	tcttgtggc	cacatggagt	gacctgggcc	tctgcaagaa	120
gcgcccgaag	cctggaggat	ggaacactgg	gggcagccga	tacccggggc	aggcagccc	180
tggaggcaac	cgctaccac	ctcaggggcgg	ttgtggctgg	gggcagccctc	atggtgtgg	240
ctggggcag	cctcatggtg	gtggctgggg	gcagccccat	ggtggtggct	ggggacagcc	300
tcatgggt	ggctggggtc	aaggagggtgg	cacccacagt	cagtggaaaca	agccgagtaa	360
gcaaaaaacc	aacatgaagc	acatggctgg	tgctgcagca	gctggggcag	tggtgggggg	420
ccttggccgc	tacatgctgg	gaagtgcctat	gagcaggccc	atcatacatt	tccgcagtga	480
ctatgaggac	cgttactatc	gtgaaaacat	gcaccgttac	cccaaccaag	tgtactacag	540
gcccatggat	gagtacagca	accagaacaa	ctttgtgcac	gactgcgtca	atatcacaat	600
caagcagcac	acggtcacca	caaccaccaa	gggggagaac	ttcaccgaga	ccgacgttaa	660
gatgatggag	cgcgtggttg	agcagatgtg	tatcaccagg	tacgagaggg	aatctcaggc	720

- 7 -

ctattaccag agaggatcga gcatggctt ctttcctct ccacctgtga tcctcctgat 780
 ctcttcctc atttcctga tagtggatg aggaaggctt tcctgtttc accatcttc 840
 taatctttt ccagcttgcggta tccacctgca gccccttgc 900
 tccatcttc ttctctttt gtcccgata ggctaataaa tacccttgc actgatggc 960
 actggaaaac atagataga cctgagatgc tggtaagcc cccttgatt gagttcatca 1020
 tgagccgtt ctaatgccag gccagtaaaa gtataacagc aaataaccat tggttaatct 1080
 ggacttattt ttggacttag tgcacaggt tgaggctaaa acaaactcga gaacagtctg 1140
 aaatacctt gcctggatac ctctggctcc ttccagcgtt agagctcagt atactaatgc 1200
 cctatcttag tagagattt atagcttta agagatattt tccatctttaaaa gaaaacccga 1260
 caacatttctt gccaggttgc tttaggaggcc acatgataactt tattcaaaaaa aatccttagag 1320
 attcttagctt cttggatgc agggctcggcc cgctggagca tgagctctgt gtgtaccgag 1380
 aactgggggtg atgtttact ttccacagta tgggtacac agcagctgtt caacaagagt 1440
 aaatattgtc acaacactga acctctggctt agaggacata ttcacagtga acataactgt 1500
 aacatataatg aaaggcttgc gggacttgc atcaaataatgtt tggtatggt gccccttggag 1560
 gcaacctccc attttagatg tttaaaggac cctatatgtt gcattctt ctttaaacta 1620
 taggttaatta aggcagctga aaagtaaattt gccttctaga cactgaaggc aaatctcctt 1680
 tgtccatttta cctggaaacc agaatgattt tgacatacag gagagctgc gttgtgaaag 1740
 caccatcatc atagaggatg atgttaattaa aaaatggtca gtgtgcaaaag aaaagaactg 1800
 ctgcatttc ttatcttgc ttccataattt gtcaaaaaacc agaatttagt caagttcata 1860
 gtttctgttta ttggcttttgc aatcaaagaa tagggagaca atctaaaaaa tatcttaggt 1920
 tggagatgac agaaatatgtt ttgatttgc gttggaaaag aaattctgtt aatgttaatt 1980
 aaagtaaaat tattccctga attgttttgc attgtcacctt agcagatatg tattactttt 2040
 ctgcaatgtt attattgttgc tgacatttttgc ggttatctat gtaaaaatataatgttat 2100
 aaaatataatgtt ttgcataatggc cagacttgcg agttttttttt agagcagtttta acatctgaaag 2160
 tgtctaatgc attaactttt gtaaggtactt gaaatactttaa tatgtggaa acccttttgc 2220
 gtggcccttta ggcttacaat gtgcactgaa tcgttttcatg taagaatcca aagtggacac 2280
 cattaacagg tcttttgcattt atgcatgttac ttatattttt ctatatttttgc aacttttgcatt 2340
 gttttttttt tgttatataaa aaaaattgtt aatgtttat aatctgactgaa aattaaacgaa 2400
 gcaagatgac gcacc 2415

Mink PrP genomic DNA (SEQ ID NO:2; GenBank Accession No. S46825)

tcattttgtt ttgttttgcg ataaaggccatc atgggtaaaaa gcccacatagg 60
 cagctggctc ctgggttctt ttgtggccac atgggtgtac atggcttctt gcaagaagcg 120
 gccaaaggctt ggaggaggatg ggaacactgg gggggccgcg taccctggcc agggcagtcc 180
 tggaggcaac cgctacccac cccagggtgg tggcgctgg ggccagcccc acgggggtgg 240
 ctggggacac cccccacgggg gttggctggg tcagccccac ggggggtggct ggggacagcc 300
 gcatgggtgc ggtggctggg gtcaagggtgg tgggagccac ggtcagttgg gcaagcccg 360
 taagcccaaa accaacatga agcatgtggc gggagccgcg gcaagccgggg cggtcggtgg 420
 gggccctgggc ggctacatgc tggggagccgc catgagcagg ccccttcatttcc attttggca 480
 cgactatgag gaccgctact accgtgagaa catgtacccgc tacccttcaacc aagtgtacta 540
 caagccgggt gatcagtaca gcaaccagaa caacttcgtg catgactgcg tcaacatcac 600
 ggtcaaggcg cacacgggtga ccaccaccac caaggccgcg aacttcacccgc agaccgacat 660
 gaagatcatg gagcgcgtgg tggagcagat gtgtgttcc cagttaccgcg gagatccga 720
 ggcttactac cagaggggggg cgagcccat cctttctcg ccccttccttgc tgatcttctt 780
 catcttactg ctcattctcc tgatagtggg atgaggatgg cttttccattt ctctccatcg 840
 tcttcacccctt ttacagggtt gggggggggg tgcgttccatca cagccctgtt gtttttttttgc 900
 ctcattccctg cttcttcttta tcacccatag gctaatttttttgc ttggcccttgc tggccctggg 960
 aaatgttagag cagacccagg atgctattta ttcaaggcccc catgtgttgc agtcttccatg 1020
 gggccaaatgc tagtgcagggtt ctgagaataaa cagccaaatca tcattttttgc accttagggct 1080
 gtttttttttgc tggttgcgtt tagtgcagctt gaccggggctt aaaacaatcc tcaaaacact 1140
 ttccaaataatc ttgcgttgc aaacccatgg cttctgtgc agcttagagct cagttacatttttgc 1200
 atgtcccatc ttgcgttgc ttccatagca acttggggaa gtttttttgc ccactctaaa 1260
 agaacgcgtat tgcacttccc tgcgttgcggaa acatcttgc ctttttttgc cccatcttgc 1320
 atgtatattca ttccaaatggc aaaactatgg acccttttgc ctttttttgc gtcgttgcggcc 1380
 gctaggagcc cccaaatggc ggcgttgcggaa acatcttgc ctttttttgc gtcgttgcggcc 1440
 gaggtgttccatgc gctgttgcggcc acatcttgc ctttttttgc gtcgttgcggcc 1500
 gaatgaacat aatcaacacttgc gcaaaaatgc tacaatggcc cccacactgg ggaggcagtgttgc 1560
 ctttttttttgc gtcgttgcggcc acatcttgc ctttttttgc gtcgttgcggcc 1620

- 8 -

tcttcgtaa	cctaaaactat	agataattaa	ggcagttaaa	aattgaactt	ccttccaggc	1680
cccaagagca	aatctttgtt	cacttacctg	gaaaccagaa	tgattttgac	acagaggaag	1740
gtgcagctgt	taaaaataacc	ctcatcctag	aagattgcat	catggagaaa	acgatccgta	1800
gacaaaaatg	atcgatttc	ttcattgctg	tctcgtaatt	gacagaaaacc	agaattatgt	1860
caagtcctag	tttctataat	cagctttga	atcaaagaat	ggaagtccat	ccaaaaaaaa	1920
aaaagaaaata	ccttaggtca	cccatgacag	aaatacccat	tcaggttaga	aaaaaggaat	1980
tctgttaact	gttatttaag	taaggcaaaa	ttattgtccg	gattgttcga	tatcatcagc	2040
tagcagataa	attagcattc	tgcaatgttc	ccggcttgca	ctgtgcgggt	atttgatgtt	2100
aaaaaaaaatt	attatatata	ttgtgtatga	caaacttaga	agtttttgct	agaggagtt	2160
acatctgata	tatctaattgc	accaccagtt	ttggaaaggta	ctaaataactt	aatatgtaga	2220
aatccttttgc	cgtggtcctc	aggcttacac	gtgcactgaa	tagttttgt	tgatagagcc	2280
catgtggct	tcgaaaatatg	catgtacttt	atattttcta	tatttgtaa	tgggcattgt	2340
cttgtataaa	aaatgtataa	acattcgaac	tcttgacttag	aattaaacag	gaactgagtg	2400
tgtcccatgt	gtttgcagtg	acattcacca	ccgcacccctg	tgttgg	.	2446

Syrian Hamster PrP cDNA (SEQ ID NO:3; GenBank Accession No. M14054)

tccatttaggc aacccatcat tttctcacct tccccattat gtaacgggg caatgggttc 120
tggaccagtc ttccattaaa gatgatttt atagtcggtg agcgcggca gggagtgatg 180
acacctgggg ggggttaaa ccgtacaatc ccttaaaccac gtctggagcg gtgactcatt 240
tccccagggg gaagtggcgc ggccattggg gagcacgacg caagccccgc cccaccggc 300
ccggccccgc cctgtaccc ctccctgactc actgccccgc ccgctcccccc gccggcggtccg 360
agcagcagac cgagaaggca catcgagttc actcgctcgcg tcgggtggcag gtaagcggct 420
tctgaagct ggccccggg agggtgctgg agccaggccct cggtaagccct tcggcttcccc 480
agagccaagc ccggcttact ccggctctcg gggcgctgag gcccggggc tgaggttgag 540
tctggctggg aggtgaccgc gcacccgcag ccgcgcgtct cttgaggga ccgaacccca 600
ggagaggcca ggagccatcc ctccctcccg agcccggtc accccccagag tcgctcgggg 660
atggggatg gggatgggg tggcatctt tgactgtcggt ttgctgtttt cttctctt 720
tgtaatagct acagcgaaca taatttacc cagggttcca ccgtggtctc gtccgtcctc 780
ggcatcttc aqtcqaqtac atacccaagg 810

Sheep PrP cDNA (SEQ ID NO:4; GenBank Accession No. AJ223072)

atgggtaaaa	gccccatagg	cagttggatc	ctgggtctct	ttgtggccat	gtggagtgac	60
gtgggcctct	gcaaaagcg	acccaaaact	ggcggaggat	ggaacactgg	ggggagccga	120
tacccgggac	aggcgatcc	tggaggcaac	cgctatccac	ctcaggggagg	gggtggctgg	180
ggtcagcccc	atggaggtgg	ctggggccaa	cctcatggag	gtggctgggg	tcagccccat	240
ggtgtgtggct	ggggacagcc	acatggtgtt	ggaggtctggg	gtcaagggtgg	tagccacagt	300
cagtggaaaca	agcccagtaa	gccccaaaacc	aacatgaagc	atgtggcagg	agctgtcga	360
gctggagcag	tggtaggggg	ccttgggtggc	tacatgtctgg	gaagtgcct	gagcagccct	420
cttatacatt	ttggcaatga	ctatgaggac	cgttactatac	gtggaaaacat	gtaccgttac	480
cccaaccaag	tgtactacag	accagtggat	cagtatagta	accagaacaa	ctttgtgcat	540
gactgtgtca	acatcacagt	caagcaacac	acagtcacca	ccaccaccaa	gggggagaac	600
ttcacccggaaa	ctgacatcaa	gataatggag	cgagttgggtgg	agcaaatgt	catcacccag	660
taccagagag	aatccccaggc	ttattaccaa	agggggggcaa	gtgtgatcct	cttttcttcc	720
ccctctgtga	tcctcctcat	ctctttccctc	atttttctca	tagtaggata	ggggcaacct	780
tcctgttttc	attatcttct	taatcttgc	caggtgggggg	gagggaggtgt	ctacctgcag	840
ccctgttagtg	gtgggtgtctc	atttcttgc	tctctcttgc	tacctgtata	ataataccct	900
tggcgcttac	agcactggga	aatgacaagc	agacatgaga	tgctgtttat	tcaagtccca	960
ttagctcagt	attctaatgt	cccatcttag	cagtgttttt	gtagcaattt	tctcattttgt	1020
ttcaagaaca	cctgactaca	tttccctttt	ggaatagcat	ttctgccaag	tctggaaagga	1080
ggccacataaa	tattcattca	aaaaaaacaaa	actggaaatc	tttagttcat	agacccaggg	1140
tccaccctgt	tgagagcatg	tgtccctgtgt	ctgcagagaa	ctataaaagga	tattctgcat	1200
tttgcagggtt	acatttgcag	gtaacacagc	catctattgc	atcaagaatg	gatattcatg	1260
caaccttta	cttatgggca	gaggacatct	tcacaaggaa	tgaacataat	acaaaaggctt	1320
ctgagactaa	aaaattccaa	catatggaaag	aggtgcctt	ggtggcagcc	ttccattttg	1380
tatgtttaag	cacccatcaag	tgatattcct	ttcttttagta	acataaaagta	tagataatta	1440
aggtaaccta	attaaaactac	cttcttagaca	ctgagagcaa	atctgttgtt	tatctggaaac	1500

- 9 -

Bovine PrP cDNA (SEQ ID NO:5; GenBank Accession No. X55882)

atgggtaaaa	gccacatagg	cagttggatc	ctggttctct	tttgggccat	gtggagtgac	60
gtggggctct	gcaagaagcg	accaaaaacc	gggaggaggat	ggaacactgg	ggggagccga	120
tacccaggac	aggcagtc	tggaggcaac	cgttatccac	ctcaggggagg	gggtggctgg	180
ggtcagcccc	atggaggtgg	ctggggccag	cctcatggag	gtggctgggg	ccagectcat	240
ggagggtggt	ggggtcagcc	ccatgggtgt	ggctggggac	agccacatgg	tggtgaggc	300
tggggtcaag	gtggtaccca	cggtaatgg	aacaaacccca	gtaagccaaa	aaccaacatg	360
aagcatgtgg	caggagctgc	tgcagctgg	gcagtggtag	ggggcccttgg	tggctacatg	420
ctgggaagtg	ccatgagcag	gcctttata	cattttggca	gtgactatga	ggaccgttac	480
tatcgtaaaa	acatgcaccc	ttaccccaac	caagtgtact	acaggccagt	ggatcagtagt	540
agtaaccaga	acaactttgt	gcatgactgt	gtcaacatca	cagtcaagga	acacacagtc	600
accaccacca	ccaaggggga	gaacttcacc	gaaactgaca	tcaagatgtat	ggagcgagtg	660
gtggagcaaa	tgtgcattac	ccagtaccag	agagaatccc	aggcttatta	ccaacgaggg	720
gcaagtgtga	tccttttctc	ttccccctct	gtgatcctcc	tcatctttt	cctcattttt	780
ctcatagtag	gatag					795

Chicken PrP cDNA (SEQ ID NO:6; GenBank Accession No. M61145)

gaattccctc	ggcagccagc	tcctccctct	cgctattttat	tcctttctcc	ccccccctacg	60
ctggatctgg	atcatctcaa	gccgagcggt	gacggcttct	tggatcgctc	atacataaaat	120
atctgtgagt	cagaggaage	aaccaccgac	ccaaagacct	caccccgagc	catggctagg	180
ctcctcacca	cctgctgcct	gctggccctg	ctgctcgccg	cctgcaccga	cgtcgccctc	240
tccaaagaagg	gcaaaggcaa	acccagtgg	gggggttggg	gcccggggag	ccatcgccag	300
cccgctacc	cccggccagcc	gggcgtaccct	cataacccag	ggtaccccca	taacccaggg	360
taccccccaca	accctggcta	tccctataac	cccggttacc	cccagaaccc	tggctacccc	420
cataacccag	gttacccagg	ctggggtaaa	ggctacaacc	catccagcgg	agaagttac	480
cacaaccaga	agccatggaa	acccccc当地	accaacttca	agcacgtggc	gggggcagca	540
gcggcgggt	ctgtgggtgg	gggcttgggg	gctacgcca	tggggcgcgt	tatgtcaggg	600
atgaactacc	acttcgatag	acccgatgag	taccgtatgt	ggagtgagaa	ctcggcgcgt	660
tatcccaacc	gggtttacta	ccgggattac	agcagccccg	tgccacagga	cgtttcgtg	720
gccgattgct	ttaacatcac	agtactgag	tacagcattt	gccctgctgc	caagaagaac	780
acctccgagg	ctgtggcgc	agcaaaacca	acggaggtgg	agatggagaa	caaagtgg	840
acgaaggtga	tccgcgagat	gtgcgtgcag	cagtaccgcg	agtaccgcct	ggcctcggc	900
atccagctgc	accctgtga	cacctggctc	gccgttctcc	tcctcttct	caccaccctt	960
tttgcgtgc	actgtatgg	tgccgtggcc	cgccctgtgt	gcagttagat	gacatcggt	1020
ccccgtgccc	accatgggg	tgttcttgc	cctcgctttt	gtccatcttt	gttgaagatg	1080
tccccccgt	gcctcccccgc	aggctctgt	tggggcaaat	gggagggat	tttgcctgt	1140
cctggcgtg	gcaggacggc	tgcgtgtgt	ggagtgggat	gccccaaaaaa	tggcctcac	1200
cacttctcc	tccttcttct	ttctggggcg	gagatatgg	ctcgccagc	cccttattgtc	1260
cctgcagag	cgtatctgaa	aatcctttt	gctaacaacg	agggttttac	ctaatctgt	1320
tagccccagt	gacagcagag	cgcctttccc	caggccacac	caaccccaag	ctgaggtgt	1380
tggcagccac	acgtccccatg	gaggctgtat	gtttttgggg	cgtcccaacg	aacaccctgg	1440
gctactgagg	tgcattttaa	gtcttttaat	ctgccaatcc	caacccattac	gtgttagatag	1500
gaactgcctg	ctctgcattt	tgcatgtgc	aaacaccctc	tgccgcagcg	ccccccaaat	1560
agagtattt	gggaatagtg	aggctgaagc	cacagcagct	tgggattggg	ctcatcatat	1620
caatccatga	tgctttgtt	ccagctgagc	ctcactgcct	ttttatagcc	tgcccagagg	1680
aaggcgcgc	tgctaaatgc	ccaaaaaggt	aacactgagg	aaaagctt	tccaatgtat	1740
gatagagaac	gagtgcatc	cgcacagatc	agccatgggg	gcatgtttt	ccatcagccc	1800
caaaacccaa	aggatgctaa	aatgcagcca	aaggggaaatc	aagcacgcag	ggaaggactt	1860
gaatcagctc	aactggattt	aatatggccaa	aggcatgagt	agaacaaacg	gcaaggggat	1920
gctggagatc	cacccctgt	gagcaaattt	ttcgatgcag	ccaaatggaaac	tattgttct	1980
tgtcttcag	ttgtctgt	tgtgtacata	ggtgttagca	tatgtaaatgt	tacacgtgt	2040
aagctgctcg	caccgcgtag	agctaataatg	tatcatgtat	gtgggcactg	aatgccaccg	2100
ttggccatac	ccaaccgtcc	taaaacgattt	tcacgtcgct	gtaacttaag	tggagataca	2160
cttcaat	attcagcaaa	aggaaattc				2188

Mouse PrP cDNA (SEQ ID NO:7; GenBank Accession No. M13685)

aattccttca	gaactgaacc	atttcaaccg	agctgaagca	ttctgccttc	ctagtggtac	60
cagtccaaatt	taggagagcc	aagcagacta	tcagtcata	tggcaaccc	tggctactgg	120
ctgtggcc	tctttgtgac	tatgtggact	gatgtcgcc	tctgcaaaaaa	gcccccaaaag	180
cctggagggt	ggaacaccgg	tggagccgg	tatccgggc	agggaaagccc	tggaggcaac	240
cgttacccac	ctcagggtgg	cacccggggg	cagccccacg	gtgggtggct	gggacaaccc	300
catggggcga	gctggggaca	acccatgtgt	ggtagttggg	gtcagccca	tggcgttgg	360
tggggccaa	gagggggatc	ccataatcag	tggaaacaacg	ccagcaaacc	aaaaaccaac	420
ctcaagcatg	tggcaggggc	tgcggcagct	ggggcagtag	tggggccct	tgggtggctac	480
atgctgggg	gcgcgtgt	caggccatg	atccattttgc	gcaacactg	ggaggaccgc	540
tactaccgtg	aaaacatgt	ccgcattacc	aaccaagtgt	actacaggcc	agtggatcag	600
tacagcaacc	agaacaactt	cgtgcacgac	tgctgtcaata	tcaccatcaa	gcagcacacg	660
gtcaccacca	ccaccaaggg	ggagaacttc	accgagaccg	atgtgaagat	gatggagcgc	720
gtgggtgg	agatgtgcgt	caccctgtac	cagaaggagt	cccaggccct	ttacgacggg	780
agaagatcca	gcagcaccgt	gctttctcc	tccctctgt	tcatccctct	catctcttcc	840
ctcatcttcc	tgatgtggg	atgagggagg	ccttctgt	tgttcttc	cattctcg	900
gtctaggctg	ggggaggggt	tatccacctg	tagcttttgc	aattgaggtg	gttctcatcc	960

- 11 -

ttgcttctct	gtgtccccca	taggctaata	cccctggcac	tcatggggcc	tggaaatgt	1020
acagtagacc	agttgtcttt	tgcttcaggt	ccctttgatg	gagtctgtca	tcagccagtg	1080
ctaacacccgg	gccaataaga	atataacacc	aaataactgc	tggctagtg	gggcttggtt	1140
ttggcttagt	gaataaaatac	tggtgtatcc	cctgacttgt	acccagagta	caaggtgaca	1200
gtgacacatg	taacttagca	taggcaaagg	gttctacaac	caaagaagcc	actgtttggg	1260
gatggcgccc	tggaaaacag	cctcccacct	gggatagcta	gagcatccac	acgtggaatt	1320
ctttcttac	taacaaacga	tagetgtattg	aaggcaacaa	aaaaaaaaaa	atcaaattgt	1380
cctactgacg	ttgaaagcaa	acctttgttc	attcccgagg	cactagaatg	atcttttagcc	1440
ttgcttggat	tgaacttagga	gatcttgact	ctgaggagag	ccagccctgt	aaaaagcttg	1500
gtcctcctgt	gacgggaggg	atggtaagg	tacaaaggt	agaaacttga	gtttcttcat	1560
ttctgtctca	caattatcaa	aagctagaat	tagttctgc	cctatgttcc	tgtacttcta	1620
tttgaactgg	ataacagaga	gacaatctaa	acattcttt	aggctgcaga	taagagaagt	1680
aggctccatt	ccaaagtggg	aaagaaaattc	tgcttagatt	gtttaatca	ggcaaaaattt	1740
gttcctgaag	ttgctttta	ccccagcaga	cataaaactgc	gatagttca	gtttgcactg	1800
tggattttct	gtatagaata	tataaaacat	aacttcaagc	ttatgttttc	ttttttaaaac	1860
atctgaagta	tgggacgccc	tggccgttcc	atccagttact	aaatgttac	cgtgtgaccc	1920
ttgggcttcc	agcgtgcact	cagtccgta	ggattccaaa	gcagaccctt	agctggtctt	1980
tgaatctgca	tgtacttcc	gtttctata	tttgcataactt	tgcatgtatt	ttttttgtc	2040
ataaaaaaag	tttataaaatg	tttgcataca	gactgacatt	aaatagaagc	tatgatg	2097

Sheep PrP cDNA (SEQ ID NO:8; GenBank Accession No. X79912)

gcagagaagt	catcatggtg	aaaagccaca	taggcagttg	gatcctggtt	ctctttgtgg	60
ccatgtggag	tgacgtgggc	ctctgcaga	agcgacccaa	acctggcgg	ggatggaaaca	120
ctggggggag	ccgatacccg	ggacaggggc	gtcctggagg	caaccgc	ccacctcagg	180
gaggggggtgg	ctggggtcag	ccccatggag	gtggctgggg	ccaaacctat	ggaggtggct	240
ggggtcagcc	ccatgggtgt	ggctggggac	agccacatgg	tggtgaggc	tgggtcaag	300
gtggtagcca	cagtcagttg	aacaagccca	gtaagccaaa	aaccaacatg	aagcatgtgg	360
caggagctgc	tgcaagttg	gcagtggtag	ggggccttgg	tggctacatg	ctgggaagtg	420
ccatgagcag	gcctttata	cattttggca	atgactatga	ggaccgttac	tatcgtgaaa	480
acatgtaccg	ttaccccaac	caagtgact	acagaccagt	ggtacgtat	agtaaccaga	540
acaactttgt	gcatgactgt	gtcaacatca	cagtcaagca	acacacagtc	accaccacca	600
ccaaggggga	gaacttcacc	gaaactgaca	tcaagataat	ggagcgtgt	gtggagcaaa	660
tgtgcac	ccagttaccag	agagaatccc	aggcttatta	ccaaaggggg	gcaagtgtga	720
tcctcttttc	ttccctctt	gtgatcctcc	tcatctttt	cctcattttt	ctcatagtag	780
gatagggcga	accttctgt	ttt				803

Rat PrP cDNA (SEQ ID NO:9; GenBank Accession No. NM_012631)

atggcgaacc	ttggctactg	gctgtggcc	ctctttgtga	ctacatgtac	tcatgttggc	60
ctctgcaaaa	agcggccaaa	gcctggaggg	tggaaactcg	gtggaagccg	gtaccctggg	120
cagggaaagcc	ctggaggcaa	ccgttaccca	cctcagactg	gtggtaactg	ggggcagccc	180
catgggtgt	gctggggaca	acctcatgtt	ggtggctggg	gacaacctca	tggtggtggc	240
tgggtcagc	cccatggccc	gggctggagt	caaggagggg	gtaccatcaa	tcaagtggaaac	300
aagcccagca	agccaaaaac	caaccccaag	catgtggcag	gggctggccg	agctggggca	360
gtagtgggg	gccttgggt	ctacatgtt	gggagtgcca	tgagcaggcc	catgctccat	420
tttggcaacg	actggggaga	ccgctactac	cgagaaaaca	tgtaccgtt	ccctaaccaa	480
gtgtactaca	ggccgggtga	tcaagtacagc	aaccagaaca	acttcgtgca	cgactgtgtc	540
aatatccacca	tcaagcagca	tacagtccacc	accaccacca	agggggagaa	cttcacggag	600
accgacgtga	agatgatgga	gcgtgtggtg	gagcagatgt	gcttcaccca	gtatcagaag	660
gagtcccagg	cctattacga	cgggagaaga	tctagcgccg	tgcctttctc	ctccctctt	720
gtgatcctcc	tcatctctt	cctcatcttc	ctgatcgtgg	gatga		765

As used herein, "prion disease" refers to any disease or condition in a subject, the pathogenesis of which involves a prion protein other than PrP^C of the species of the subject.

- 12 -

A prion disease will typically but not necessarily be a transmissible spongiform encephalopathy.

As used herein, “transmissible spongiform encephalopathy” and, equivalently, “(TSE)” shall mean any prion disease that is associated with spongiform encephalopathy and is communicable from one individual to another. As prion diseases can include entities other than TSE, this term refers to at least a subset of all prion diseases. At present TSE includes Creutzfeldt-Jakob disease, kuru, Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, bovine spongiform encephalopathy, and scrapie.

As used herein, “Creutzfeldt-Jakob disease” and, equivalently, “(CJD)” refers to the TSE that naturally occurs in humans. CJD includes sporadic, genetic (familial), and infectious (i.e., variant and iatrogenic) forms. CJD is a well described entity in the medical literature, and until now has been widely believed to be a uniformly fatal neurodegenerative disease for which there is no effective form of treatment.

As used herein, “variant Creutzfeldt-Jakob disease” and, equivalently, “(vCJD)”, also referred to in the literature as new variant Creutzfeldt-Jakob disease (nvCJD), refers to CJD attributable to the BSE prion. It can be distinguished from sporadic CJD not only by the prion involved but also by certain clinical and preclinical features. See Aguzzi A (2000) *Haematologica* 85:3-10; Hill AF et al. (1997) *Nature* 389:448-50; Bruce ME et al. (1997) *Nature* 389:498-501; Will R et al. (1996) *Lancet* 347:921-5.

As used herein, “iatrogenic Creutzfeldt-Jakob disease” and, equivalently, “(iCJD)” refers to any form of CJD that is attributable to work- or treatment-related exposure to prion protein that is associated with CJD.

As used herein, “bovine spongiform encephalopathy” and, equivalently, “(BSE)” shall refer to the TSE that occurs naturally in cows and cattle.

As used herein, “scrapie” refers to the TSE that occurs naturally in sheep and goats, as well as to experimental models of scrapie. Scrapie in sheep has been recognized and described in the literature for over 300 years. For a review, see O’Rourke KI (2001) *Vet Clin North Am Food Anim Pract* 17:283-300.

As used herein, a “prion protein that is associated with a prion disease” refers to any prion protein involved in the pathogenesis of a prion disease. A prion protein that is associated with a prion disease can be a prion found in nature. Alternatively, prion protein that is associated with a prion disease can be a prion protein made de novo or modified from

its natural form through human activity, e.g., by in vitro synthesis, chemical synthesis, chemical derivatization, or genetic alteration. Chemical alteration includes, without limitation, altered glycosylation. In a preferred embodiment, a prion protein that is associated with a prion disease is a prion protein found in nature, e.g., PrP^{Sc}. In one embodiment, a prion protein that is associated with a prion disease is a truncated or genetically modified form of a prion protein found in nature. A genetically modified form of a prion protein found in nature includes a fusion protein involving at least a substantial portion of a prion protein as one component, a prion protein that differs from a prion protein found in nature by one or more conservative amino acid substitutions, and allelic variants of the prion protein found in nature.

Naturally occurring residues can be divided into the following classes based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; (3) acidic: Asp, Glu; (4) basic: Asn, Gln, His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. Thus, for example, conservative amino acid substitutions can involve the exchange of a member from one of these classes for another member from the same class. Non-conservative amino acid substitutions can involve the exchange of a member of one of these classes for a member from another class.

A conservative amino acid substitution can involve a substitution of a native amino acid residue with another residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues that are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties.

As used herein, "prion protein:scrapie form (PrP^{Sc})" refers to any of a number of naturally occurring, species-specific, proteinase K-resistant forms of prion protein associated with prion disease. Specific examples include, but are not limited to, the following: human PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:10; bovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:11; bovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:12; ovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:13; ovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:14; and murine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:15.

- 14 -

Human PrP^{Sc} (SEQ ID NO:10; GenBank Accession No. AAE81600)

MANLGCWMLV	LFVATWSDLG	LCKKRKPQPG	WNTGGSRYPG	QGSPGGNRYP	PQGGGGWGQP	60
HGGGWGQPHG	GGWGQPHGGG	WGQPHGGGWG	QGGGTHSQWN	KPSKPKTNMK	HMAGAAAAGA	120
VVGGLGGYML	GSAMSRPIIH	FGSDYEDRYY	RENMHRYPNQ	VYYRPMDEYS	NQNNFVHDCV	180
NITIKQHTVT	TTTKGENFTE	TDVKMMERVV	EQMCITQYER	ESQAYYQRGS	SMVLFSSPPV	240
ILLISFLIFL	IVG					253

Bovine PrP^{Sc} (SEQ ID NO:11; GenBank Accession No. AAE81601)

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP	GGWNTGGSRY	PGQGSPGGNR	YPPQGGGGWG	60
QPHGGGWGQP	HGGGWGQPHG	GGWGQPHGGG	WGQPHGGGWG	QGGGTHGQWN	KPSKPKTNMK	120
HVAGAAAAGA	VVGGLGGYML	GSAMSRPLIH	FGSDYEDRYY	RENMHRYPNQ	VYYRPVDQYS	180
NQNNFVHDCV	NITVKEHTVT	TTTKGENFTE	TDIKMMERVV	EQMCVTQYQK	ESQAYYDQGA	240
SVILFSSPPV	ILLISFLIFL	IVG				263

Bovine PrP^{Sc} (SEQ ID NO:12; GenBank Accession No. CAA39368)

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP	GGWNTGGSR	YPGQGSPGGN	RYPPQGGGGW	60
QPHGGGWGQ	PHGGGWGQPH	GGWGQPHGG	GWGQPHGGGG	WGQGGTHGQW	NKPSKPKTNM	120
KHVAGAAAAG	AVVGGLGGYM	LGSAMSRPLI	HFGSDYEDRY	YRENMHRYPN	QVYYRPVDQY	180
SNQNNFVHDC	VNITVKEHTV	TTTKGENFT	ETDIKMMERV	VEQMCITQYQ	RESQAYYQRG	240
ASVILFSSPP	VILLISFLIF	LIVG				264

Ovine PrP^{Sc} (SEQ ID NO:13; GenBank Accession No. AAE81602)

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP	GGWNTGGSRY	PGQGSPGGNR	YPPQGGGGWG	60
QPHGGGWGQP	HGGGWGQPHG	GSWGQPHGGG	GWGQGGSHSQ	WNKPSKPKTN	MKHVAGAAA	120
GAVVGGLG	MLGSAMSRPL	IHFNDYEDR	YYRENMYRYP	NQVYYRPVDQ	YSNQNNFVHD	180
CVNITVKQHT	TTTTKGENF	TETDIKIMER	VVEQMCITQY	QRESQAYYQR	GASVILFSSP	240
PPVILLISFLI	FLIVG					255

Ovine PrP^{Sc} (SEQ ID NO:14; GenBank Accession No. CAA56283)

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP	GGWNTGGSR	YPGQGSPGGN	RYPPQGGGGW	60
QPHGGGWGQ	PHGGGWGQPH	GGWGQPHGG	GWGQGGSHS	QWNKPSKPKT	NMKHVAGAAA	120
AGAVVGGLG	YMLGSAMSRP	LIHFNDYED	YYRENMYRY	PNQVYYRPVD	QYSNQNNFVH	180
DCVNITVKQH	TTTTKGEN	FTETDIKIME	RVVEQMCITQ	YQRESQAYYQ	RGASVILFSS	240
PPVILLISFL	FLIVG					256

Murine PrP^{Sc} (SEQ ID NO:15; GenBank Accession No. AAE81599)

- 15 -

MANLGYWLLA	LFVTMWTDVG	LCKKRPKPGG	WNTGGSRYPG	QGSPGGNRYP	PQGGTWGQPH	60
GGGWGQPHGG	SWGQPHGGSW	GQPHGGGWGQ	GGGTHNQWNK	PSKPKTNLKH	VAGAAAAGAV	120
VGGLGGYMLG	SAMSRPMIHF	GNDWEDRYYR	ENMYRYPNQV	YYRPVDQYSN	QNNFVHDCVN	180
ITIKQHTVTT	TTKGENFTET	DVKMMERVVE	QMCVTQYQKE	SQAYYDGRRS	SSTVLFSSPP	240
VILLISFLIF	LIVG					254

As used herein, “full-length PrP^{Sc}” refers to a form of PrP^{Sc} that includes all its amino acids as it occurs in nature. It is to be distinguished, for example, from a truncated form of PrP^{Sc}, described elsewhere herein. A full-length PrP^{Sc} can, however, be incorporated into a PrP^{Sc} conjugate or PrP^{Sc} fusion protein.

As used herein, a “derivative of PrP^{Sc}” refers to a chemical or genetic derivative of a naturally occurring form of PrP^{Sc}, including PrP^{Sc} with non-native glycosylation, covalent or non-covalent conjugates formed between PrP^{Sc} and another compound, PrP^{Sc} fusion proteins, and any combination thereof. A “derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}” refers to a chemical or genetic derivative of an N-terminally truncated form of PrP^{Sc}, including such truncated forms of PrP^{Sc}: (i) with non-native glycosylation, (ii) as part of a covalent or non-covalent conjugate formed with another compound, (iii) as part of a fusion protein, or (iv) any combination thereof. In preferred embodiments the fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} refers to a fragment lacking one or more, up to and including all, of the octarepeats (e.g., GGGWGQPH (SEQ ID NO:16) and GGSWGQPH (SEQ ID NO:17)). See Flechsig E et al. (2000) *Neuron* 27:399-408.

A truncated form of a prion protein found in nature is identical in primary sequence to the prion protein found in nature except for the absence of one or more amino acid residues from the N-terminal end, the C-terminal end, or both the N-terminal and the C-terminal ends. Truncated forms can also include deletion mutants, in which an internal sequence is omitted without changing either the N-terminal end or the C-terminal end. In a preferred embodiment, a truncated prion protein lacks one or more, up to and including all, N-terminal octarepeats (e.g., GGGWGQPH and GGSWGQPH). See Flechsig E et al. (2000) *Neuron* 27:399-408.

As used herein, a “fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}” shall refer to a truncated form of full-length PrP^{Sc} lacking one or more N-terminal amino acids normally present in full-length PrP^{Sc}. In a preferred embodiment, the fragment

- 16 -

lacks one or more, up to and including all, of the octarepeats (e.g., GGGWGQPH and GGSWGQPH). See Flechsig E et al. (2000) *Neuron* 27:399-408.

The methods of the instant invention employ immunostimulatory nucleic acids. In the preferred embodiment, the immunostimulatory nucleic acid is a CpG nucleic acid. The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases).

Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Other such modifications are well known to those of skill in the art.

The immunostimulatory oligonucleotides of the instant invention can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a β -D-ribose unit and/or a natural

nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" *Synthesis and Properties & Synthesis and Analytical Techniques*, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth Methods* 7:331-417. An oligonucleotide according to the invention can have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular β -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

For example, the invention relates to an oligonucleotide which comprises one or more modifications and wherein each modification is independently selected from:

- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
- b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge,
- c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
- d) the replacement of a β -D-ribose unit by a modified sugar unit, and
- e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate, NR^1R^2 -phosphoramidate, boranophosphate, α -hydroxybenzyl phosphonate, phosphate-(C₁-C₂₁)-O-alkyl ester, phosphate-[(C₆-C₁₂)aryl-(C₁-C₂₁)-O-alkyl]ester, (C₁-C₈)alkyl-phosphonate and/or (C₆-C₁₂)-arylphosphonate bridges, (C₇-C₁₂)- α -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein (C₆-C₁₂)aryl, (C₆-C₂₀)aryl and (C₆-C₁₄)aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where R¹ and R² are, independently of each other, hydrogen, (C₁-C₁₈)-alkyl, (C₆-C₂₀)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, preferably hydrogen, (C₁-C₈)-alkyl, preferably (C₁-C₄)-alkyl and/or methoxymethyl, or R¹ and R² form, together with

the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa 1993, Chapter 16, pp. 355ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazone, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a β -D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Sturchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine.

A β -ribose unit or a β -D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from β -D-ribose, α -D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-O-(C₁-C₆)alkyl-ribose, preferably 2'-O-(C₁-C₆)alkyl-ribose is 2'-O-methylribose, 2'-O-(C₂-C₆)alkenyl-ribose, 2'-[O-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl]-ribose, 2'-NH₂-2'-deoxyribose, β -D-xylo-furanose, α -arabinofuranose, 2,4-dideoxy- β -D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

A natural nucleoside base can be replaced by a modified nucleoside base, wherein the modified nucleoside base is for example selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C₁-C₆)-alkyluracil, 5-(C₂-C₆)-alkenyluracil, 5-(C₂-C₆)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C₁-C₆)-alkylcytosine, 5-(C₂-C₆)-alkenylcytosine, 5-(C₂-C₆)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine,

- 19 -

5-bromocytosine, N²-dimethylguanosine, 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine or other modifications of a natural nucleoside bases. This list is meant to be exemplary and is not to be interpreted to be limiting.

The oligonucleotides of the present invention are nucleic acids that contain specific sequences found to elicit an immune response. These specific sequences that elicit an immune response are referred to as "immunostimulatory motifs", and the oligonucleotides that contain immunostimulatory motifs are referred to as "immunostimulatory nucleic acid molecules" and, equivalently, "immunostimulatory nucleic acids" or "immunostimulatory oligonucleotides". The immunostimulatory oligonucleotides of the invention thus include at least one immunostimulatory motif.

In one embodiment of the invention the immunostimulatory oligonucleotides include immunostimulatory motifs which are "CpG dinucleotides". A CpG dinucleotide can be methylated or unmethylated. An immunostimulatory nucleic acid containing at least one unmethylated CpG dinucleotide is a nucleic acid molecule which contains an unmethylated cytosine-guanine dinucleotide sequence (i.e., an unmethylated 5' cytosine followed by 3' guanosine and linked by a phosphate bond) and which activates the immune system; such an immunostimulatory nucleic acid is a CpG nucleic acid. CpG nucleic acids have been described in a number of issued patents, published patent applications, and other publications, including U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068.

An immunostimulatory nucleic acid containing at least one methylated CpG dinucleotide is a nucleic acid which contains a methylated cytosine-guanine dinucleotide sequence (i.e., a methylated 5' cytosine followed by a 3' guanosine and linked by a phosphate bond) and which activates the immune system. In other embodiments the immunostimulatory oligonucleotides are free of CpG dinucleotides. These oligonucleotides which are free of CpG dinucleotides are referred to as non-CpG oligonucleotides, and they have non-CpG immunostimulatory motifs. The invention, therefore, also encompasses nucleic acids with other types of immunostimulatory motifs, which can be methylated or unmethylated. The immunostimulatory oligonucleotides of the invention, further, can include any combination of methylated and unmethylated CpG and non-CpG

- 20 -

immunostimulatory motifs. In some embodiments the immunostimulatory oligonucleotide is not an antisense oligonucleotide.

As used herein, a “Toll-like receptor (TLR) that signals in response to the CpG nucleic acid” refers to any TLR that engages or initiates an intracellular signaling pathway associated with the development of an immune response, as a result of contacting the TLR with CpG nucleic acid. The pathway typically involves the adaptor protein MyD88 and subsequent downstream molecules including TRAF, IRAK, Jun, Erk, p38 MAPK, and NF- κ B. The TLRs are a family of at least ten highly conserved receptors that share as a common feature a cytoplasmic Toll homology IL-1 receptor (TIR) domain believed to be involved in such signaling. TLR9 is reported to be the natural receptor for CpG nucleic acid.

As to CpG nucleic acids, it has recently been described that there are different classes of CpG nucleic acids. One class is potent for activating B cells but is relatively weak in inducing IFN- α and NK cell activation; this class has been termed the B class. The B class CpG nucleic acids typically are fully stabilized and include an unmethylated CpG dinucleotide within certain preferred base contexts. See, e.g., U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Another class is potent for inducing IFN- α and NK cell activation but is relatively weak at stimulating B cells; this class has been termed the A class. The A class CpG nucleic acids typically have stabilized poly-G sequences at 5' and 3' ends and a palindromic phosphodiester CpG dinucleotide-containing sequence of at least 6 nucleotides. See, for example, published patent application PCT/US00/26527 (WO 01/22990). Yet another class of CpG nucleic acids activates B cells and NK cells and induces IFN- α ; this class has been termed the C class. The C class CpG nucleic acids typically are fully stabilized, include a B class-type sequence and a GC-rich palindrome or near-palindrome. This class has been described in published patent application PCT/US02/26468 (WO 03/015711), the entire content of which is incorporated herein by reference.

Immunostimulatory oligonucleotides are effective in vertebrates. Different immunostimulatory oligonucleotides can cause optimal immune stimulation depending on the type of subject and the sequence of the immunostimulatory oligonucleotide. Many vertebrates have been found according to the invention to be responsive to the same class of immunostimulatory oligonucleotides, sometimes referred to as human specific immunostimulatory oligonucleotides. Rodents, however, respond to different nucleic acids.

- 21 -

Immunostimulatory oligonucleotides causing optimal stimulation in humans may not generally cause optimal stimulation in a mouse and vice versa. An immunostimulatory oligonucleotide causing optimal stimulation in humans often does, however, cause optimal stimulation in other animals such as cow, horses, sheep, etc. For example, within Class B CpG ODN, preferred immunostimulatory sequences have been identified for use in mice (ODN 1826, 5'- TCCATGACGTTCTGACGTT -3', SEQ ID NO:18) and for use in humans (ODN 2006, 5'- TCGTCGTTTGTGCGTTTGTGCGTT -3', SEQ ID NO:19). One of skill in the art can identify the optimal immunostimulatory nucleic acid sequences useful for a particular species of interest using routine assays described herein and/or known in the art, using the guidance supplied herein.

As used herein, the term "treat" as used in reference to a disease or condition shall mean to intervene in such disease or condition so as to prevent or slow the development of, slow the progression of, halt the progression of, or eliminate the disease or condition. Thus the phrase "to treat the prion disease" as used herein means to prevent or slow the development of, slow the progression of, halt the progression of, or eliminate the prion disease.

As used herein, a "subject" refers to a human or non-human vertebrate. Preferred non-human vertebrates include feed livestock susceptible to TSE, including cows and cattle, sheep, goats, and pigs. Non-human subjects also specifically include non-human primates as well as rodents. Non-human subjects also include, without limitation, chickens, horses, dogs, cats, guinea pigs, hamsters, mink, and rabbits.

As used herein, a "subject having a prion disease" is a subject known or diagnosed to have a prion disease as disclosed herein. Generally a subject having a prion disease will have some objective manifestation of the prion disease, such as a sign, symptom, or result of a suitable diagnostic test that indicates the presence of a prion disease. In the transmissible spongiform encephalopathies, such objective manifestations can include dementia, ataxia, myoclonus, tremor, presence of protease-resistant prion protein in brain extract, and typical or characteristic abnormalities on brain CT, brain MRI, and/or EEG. This list is not meant to be limiting in any way, and those of skill in the art will recognize what criteria are suitable for making a diagnosis of prion disease in a given species in question. A subject having a prion disease shall also include any subject having a test result which specifically indicates the presence in that subject of any amount of prion protein that is associated with a prion

- 22 -

disease, since it is believed that prion protein that is associated with a prion disease is not present in a subject without a prion disease.

A subject having a prion disease can but need not necessarily have an identifiable risk factor for having a prion disease. An identifiable risk factor for having a prion disease can include a family history of prion disease, a history of consuming known or suspected prion-diseased tissue, or a history of exposure to a prion protein that is associated with a prion disease or to a product derived from a known or suspected prion-diseased tissue (e.g., through administration of pituitary extract).

As used herein, a "subject at risk of developing a prion disease" is a subject with a known or suspected exposure to prion-diseased tissue, a known or suspected exposure to prion protein that is associated with a prion disease, or a known or suspected predisposition to develop a prion disease (e.g., family history of prion disease). In one embodiment the subject at risk of developing a prion disease is a subject residing in or traveling to an area in which TSE is endemic. In one embodiment the subject at risk of developing a prion disease is a subject residing in or traveling to an area in which food or water contains or is likely to contain prion protein that is associated with prion disease. In one embodiment, a subject at risk of developing a prion disease is a subject with a known or suspected iatrogenic exposure to prion-diseased tissue, e.g., neurosurgeons, neuropathologists, pathologists, nurses, morticians, histology technicians and laboratory workers at special risk of contracting iCJD. In one embodiment, a subject at risk of developing a prion disease is a subject with a known or suspected iatrogenic exposure to prion-diseased tissue through receiving a tissue or organ allograft from a subject having a prion disease. Such tissues can include, without limitation, corneas and dural grafts.

As used herein, an "effective amount" of a substance generally refers to that amount of the substance that is sufficient to bring about a desired effect. With reference to CpG nucleic acid, an "effective amount to induce an immune response to the prion protein" shall refer to that amount of CpG nucleic acid that is sufficient to induce an immune response to a particular prion protein. The immune response can occur in vitro, in vivo, ex vivo, and any combination thereof. An immune response to a prion protein can be measured using any suitable means to determine that an immune response occurs in association with exposure of an immune cell to the prion protein. The immune response can be antigen-specific, including any of the following: production of prion protein-specific antibody, proliferation of prion

- 23 -

protein-specific lymphocytes, and cell-mediated immunity against cells expressing prion protein. The immune response can alternatively or additionally be antigen-nonspecific, including any of the following: induction of a Toll-like receptor signaling pathway, inflammation, and production of a cytokine and/or chemokine. Because prion proteins are generally believed not to evoke an immune response, any prion protein-specific immune response which occurs in association with exposure of an immune cell to a prion protein will generally indicate an immune response to the prion protein.

Also with reference to CpG nucleic acid, an "effective amount to treat the prion disease" shall refer to that amount of CpG nucleic acid that is sufficient to treat a particular prion disease. In one embodiment, an effective amount to treat the prion disease is that amount that is sufficient to slow the development of prion disease, compared to the rate of development of prion disease that would occur without CpG administration according to the instant invention. In one embodiment, an effective amount to treat the prion disease is that amount that is sufficient to prevent the development of prion disease, compared to development of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to slow the progression of prion disease, compared to the rate of progression of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to stop the progression of prion disease, compared to the progression of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to resolve prion disease, compared to the prion disease that would occur without CpG administration according to the instant invention.

Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular immunostimulatory oligonucleotide being administered, the antigen, the size of the subject, or the severity of the disease or condition.

- 24 -

One of ordinary skill in the art can empirically determine the effective amount of a particular immunostimulatory oligonucleotide and/or other therapeutic agent without necessitating undue experimentation.

Subject doses of the immunostimulatory oligonucleotides for mucosal or local delivery typically range from about 0.1 μ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically doses range from about 10 μ g to 5 mg per administration, and most typically from about 100 μ g to 1 mg, with repeated administrations being spaced days or weeks apart. Subject doses of immunostimulatory oligonucleotides for parenteral delivery for the purpose of inducing an antigen-specific immune response, wherein the compounds are delivered with an antigen but not another therapeutic agent are typically 5 to 10,000 times higher than the effective mucosal dose for vaccine adjuvant or immune stimulant applications, and more typically 10 to 1,000 times higher, and most typically 20 to 100 times higher. Doses of the immunostimulatory oligonucleotides for parenteral delivery for the purpose of inducing an innate immune response or for inducing an antigen-specific immune response when the immunostimulatory nucleic acids are administered in combination with other therapeutic agents or in specialized delivery vehicles typically range from about 0.1 μ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically parenteral doses for these purposes range from about 10 μ g to 5 mg per administration, and most typically from about 100 μ g to 1 mg, with repeated administrations being spaced days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any immunostimulatory oligonucleotide the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for CpG oligonucleotides which have been tested in humans (human clinical trials have been initiated) and for compounds which are known to exhibit similar pharmacological activities, such as other mucosal adjuvants, e.g., LT and other antigens for vaccination purposes, for mucosal or local administration. Higher doses are required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered immunostimulatory oligonucleotide. Adjusting the dose to achieve maximal efficacy based on the methods described herein and

- 25 -

other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The immunostimulatory oligonucleotide can be administered alone or with antigen or other therapeutic agent. In this context, "antigen" refers to any biological molecule capable of eliciting specific immunity. Antigens specifically include peptides (oligopeptides, polypeptides, proteins, and glycosylated derivatives thereof), and polysaccharides. Peptide antigen can be administered preformed or as a polynucleotide encoding the peptide. Also in this context, "other therapeutic agent" includes any suitable composition useful in treating prion disease, including an antibody capable of binding a prion protein. When the immunostimulatory oligonucleotide is administered with antigen or other therapeutic agent, the immunostimulatory oligonucleotide can be administered before, concurrently with, or following administration of the antigen or other therapeutic agent. The immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be formulated together or separately when the immunostimulatory oligonucleotide is administered concurrently with the antigen or other therapeutic agent. When the immunostimulatory oligonucleotide is administered before or following administration of antigen or other therapeutic agent, the immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be administered by the same route of administration or by different routes of administration. In addition, when the immunostimulatory oligonucleotide is administered before or following administration of antigen or other therapeutic agent, the immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be administered to the same site or to different sites.

The immunostimulatory oligonucleotides may be directly administered to the subject or may be administered in conjunction with a nucleic acid delivery complex. A nucleic acid delivery complex shall mean a nucleic acid molecule associated with (e.g., ionically or covalently bound to; or encapsulated within) a targeting means (e.g., a molecule that results in higher affinity binding to target cell (e.g., B cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with a sterol (e.g., cholesterol), a lipid (e.g., a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g., a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization by the target cell. However, the complex can

- 26 -

be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.

Delivery vehicles or delivery devices for delivering antigen and nucleic acids to surfaces have been described. The immunostimulatory oligonucleotide and/or the antigen and/or other therapeutics may be administered alone (e.g., in saline or buffer) or using any delivery vehicles known in the art. For instance the following delivery vehicles have been described: cochleates (Gould-Fogerite et al., 1994, 1996); emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Mowat et al., 1993, Carlsson et al., 1991, Hu et., 1998, Morein et al., 1999); liposomes (Childers et al., 1999, Michalek et al., 1989, 1992, de Haan 1995a, 1995b); live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, bacillus Calmette-Guérin, *Shigella*, *Lactobacillus*) (Hone et al., 1996, Pouwels et al., 1998, Chatfield et al., 1993, Stover et al., 1991, Nugent et al., 1998); live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex) (Gallichan et al., 1993, 1995, Moss et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999); microspheres (Gupta et al., 1998, Jones et al., 1996, Maloy et al., 1994, Moore et al., 1995, O'Hagan et al., 1994, Eldridge et al., 1989); nucleic acid vaccines (Fynan et al., 1993, Kuklin et al., 1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); polymers (e.g., carboxymethylcellulose, chitosan) (Hamajima et al., 1998, Jabbal-Gill et al., 1998); polymer rings (Wyatt et al., 1998); proteosomes (Vancott et al., 1998, Lowell et al., 1988, 1996, 1997); sodium fluoride (Hashi et al., 1998); transgenic plants (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); virosomes (Gluck et al., 1992, Mengiardi et al., 1995, Cryz et al., 1998); virus-like particles (Jiang et al., 1999, Leibl et al., 1998).

The immunostimulatory oligonucleotides may be administered by any means known to the skilled artisan. Routes of administration include but are not limited to oral, mucosal, parenteral, intravenous, intramuscular, intraperitoneal, intranasal, intratracheal, sublingual, subcutaneous, intradermal, inhalation, ocular, vaginal, and rectal.

The immunostimulatory oligonucleotides are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic

gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer R (1990) *Science* 249:1527-33, which is incorporated herein by reference.

The immunostimulatory oligonucleotides and optionally other therapeutics and/or antigens may be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

For oral administration, the immunostimulatory oligonucleotides can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose,

- 28 -

mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

- 29 -

The immunostimulatory oligonucleotides, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The immunostimulatory oligonucleotides may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the immunostimulatory oligonucleotides may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

The term "pharmaceutically-acceptable carrier" means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a

- 30 -

human or other vertebrate animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.

The immunostimulatory oligonucleotides useful in the invention may be delivered in mixtures with additional adjuvant(s), other therapeutics, or antigen(s). A mixture may consist of several adjuvants in addition to the immunostimulatory oligonucleotide or several antigens or other therapeutics.

The particular mode selected will depend, of course, upon the particular adjuvants or antigen selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.

The immunostimulatory oligonucleotides may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the immunostimulatory oligonucleotides into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, purpose of the immunization (i.e., prophylactic or therapeutic), nature and severity of the disorder, age and body weight of the patient, different doses may be necessary. The administration of a given dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units. Multiple administration of doses at specific intervals of weeks or months apart is usual for boosting the antigen-specific responses.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds,

- 31 -

increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides.

Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di-and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Examples

Example 1. CpG-ODN Protects Mice from Scrapie Prion.

Groups of 8 mice each were inoculated intraperitoneally with 100 μ l of 10% brain homogenates from mice terminally ill with RML scrapie prion strain corresponding to an infectious challenge of approximately 10^4 LD₅₀. The mice received 0.15 pmol (30 μ l of 5 nM solution) CpG-ODN (oligonucleotide 1826, 5'- TCCATGACGTTCTGACGTT -3', SEQ ID NO:18), which has been shown to be a strong inducer of innate immunity and to confer sterile immunity against certain infectious diseases. Sparwasser T et al. (2000) *Eur J Immunol* 30:3591-7. CpG-ODN was administered intraperitoneally at the time of inoculation (0h) with scrapie prions as well as 4 times at intervals of 24h (4 x q 24h); a second group received 0.15 pmol (30 μ l of 5 nM solution) CpG-ODN 7h after infection (7h) and 4 times at intervals of 24h (4 x q 24h); a third group received CpG-ODN at 7h after infection and subsequently 20 times at intervals of 24h (20 x q 24h). Controls matched for age and sex were given saline instead of CpG-ODN at the identical time intervals. Additional control experiments were also performed in uninfected mice using saline and brain homogenates of

uninfected mice. All animals were observed and scored daily for clinical signs of disease. Scrapie in mice is characterized by ataxia of gait, tremor, difficulty righting from a supine position, and tail rigidity. Occurrence of two of these four symptoms was used as the end point criterion for establishing a clinical diagnosis of scrapie. Western blots of brain homogenates were performed to confirm the diagnosis. All results were analyzed using the Student's t test (Table 1).

Table 1. Mean incubation time in C57BL/6 mice after inoculation with scrapie strain RML and treatment with CpG-ODN.

Group	Inoculation	Treatment	Regimen	Time to Terminal Disease (d) ± SD	Attack Rate
1	RML	CpG 1826	0h and 4 x q 24h	253 ± 4	8/8
2	RML	CpG 1826	7h and 4 x q 24h	250 ± 6	8/8
3	RML	CpG 1826	7h and 20 x q 24h	> 330 no disease	0/8
4	RML	Saline	0h and 4 x q 24h	183 ± 7	8/8
5	RML	Saline	7h and 4 x q 24h	181 ± 3	8/8
6	RML	Saline	7h and 20 x q 24h	181 ± 3	8/8
7	Saline	CpG 1826	0h and 4 x q 24h	No disease	0/8
8	Saline	CpG 1826	7h and 4 x q 24h	No disease	0/8
9	Saline	CpG 1826	7h and 20 x q 24h	No disease	0/8
10	Brain homogenate of uninfected mouse	CpG 1826	0h and 4 x q 24h	No disease	0/8
11	Brain homogenate of uninfected mouse	CpG 1826	7h and 4 x q 24h	No disease	0/8
12	Brain homogenate of uninfected mouse	CpG 1826	7h and 20 x q 24h	No disease	0/8

Mice infected with the RML strain which received CpG-ODN at the time of inoculation and 7h post-infection as well as 4 times at intervals of 24h showed a dramatic prolongation of survival time compared to control mice with an increase in survival time of 38% in both cases. These differences were highly significant ($p < 0.0001$). The application of CpG-ODN 7h post-inoculation and 20 times at 24h intervals led to disease-free intervals of more than 330 days. All control groups which were not inoculated with the RML strain remained disease-free, and no harmful effect of CpG-ODN application was observed.

- 33 -

These results showed that the application of CpG-ODN at the time of infection and 7h after infection led to a dramatic prolongation of survival time. This effect can be amplified when CpG-ODN are given for a longer period of time. The application of CpG-ODN for 20 times at 24h intervals results in a disease-free interval of >330 days, which indicates the great potential of CpG-ODN for post-exposure prophylaxis of people with exposure to infection. The mechanism of disease prevention remains to be determined, but it seems that the most likely explanation for this effect is a stimulation of TLR-expressing cells of the innate immune system, e.g., macrophages, monocytes, and especially dendritic cells. Sparwasser T et al. (2000) *Eur J Immunol* 30:3591-7. CpG-ODN has been known to induce resistance against other infectious diseases. Zimmermann S et al. (1998) *J Immunol* 160:3627-30. The induction of extreme prolongation of the incubation time or even resistance to prion disease was a surprising finding in the context of a completely different infectious agent.

The findings presented here show that administration of CpG-ODN prolongs the incubation time by 38% and may have the potential to prevent infection after repeated administration, even when high doses of infectivity are administered intraperitoneally. It may therefore be possible to prevent disease after inadvertent iatrogenic exposure with much lower infectious doses administered peripherally.

Example 2. Effect of Timing Between Exposure to Prion and Administration of CpG-ODN.

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1, except that the interval between injection with RML scrapie prion or control and administration of CpG-ODN or control is varied. In some groups administration of CpG-ODN is delayed as much as a month following injection with RML scrapie prion or control. In some groups administration of CpG-ODN precedes injection with RML scrapie prion or control. In some groups the number and schedule of repeated administrations of CpG-ODN is varied from Example 1. Results, measured as in Example 1, show that CpG-ODN is effective even when administered more than 7h after injection with RML scrapie prion.

Example 3. Mice Protected from Scrapie Prion by CpG-ODN Develop an Immune Response to Prion.

- 34 -

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1 or Example 2. At various time points following injection with RML scrapie prion or control and treatment with CpG-ODN or control, tissue or blood samples are obtained and analyzed for prion-specific and prion-nonspecific immune response. Presence of an immune response is determined by suitable method or measurement including, without limitation, antibody titer, enzyme-linked immunosorbent assay (ELISA), flow cytometry, cell proliferation assay, cytotoxicity assay, polymerase chain reaction (PCR) and reverse transcriptase-polymerase chain reaction (RT-PCR), Western immunoblot, Northern blot, and Southern blot. General methods for these types of measurements are standard and are suitably adapted to the specific antigen or stimulus being assayed. For example, ELISA is used to measure production of various secreted products, including antibodies, cytokines and chemokines. Cytokines and chemokines in this example include interleukin (IL)-4, IL-10, IL-6, IL-12, IL-18, interferon (IFN)- α , IFN- β , IFN- γ , tumor necrosis factor (TNF), and IP-10. Flow cytometry is used to measure cell surface and intracellular proteins, including markers associated with immune cell activation. Markers associated with immune cell activation can vary with cell type but include cluster of differentiation (CD) markers such as CD86, major histocompatibility complex (MHC), inducible cytokine receptors, and certain costimulatory molecules. Results show that CpG-ODN induces an immune response to prion protein.

Example 4. Selection of CpG-ODN.

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1 or Example 2. Various CpG-ODN are compared against ODN 1826 for their effectiveness. Results, measured as in Example 1, show that protection is related to the use of species-optimized CpG-ODN.

Example 5. Use of CpG-ODN in Alzheimer's Disease Model.

Mice genetically susceptible to developing Alzheimer's-like disease are administered CpG nucleic acid alone or CpG nucleic acid plus antigen (e.g., amyloid precursor protein or A β), either prior to or following onset of Alzheimer's-like disease. Similar mice are administered appropriate control treatment. Animals are monitored for behavioral and histologic evidence of Alzheimer's-like disease.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

- 36 -

Claims

1. A method for treating a prion disease in a subject, comprising:
administering to a subject having or at risk of developing a prion disease a CpG nucleic acid in an effective amount to treat the prion disease.
2. The method according to claim 1, wherein the administering follows exposure of the subject to a prion protein that is associated with a prion disease.
3. The method according to claim 1, wherein the prion disease is a transmissible spongiform encephalopathy (TSE).
4. The method according to claim 1, wherein the prion disease is scrapie.
5. The method according to claim 1, wherein the prion disease is bovine spongiform encephalopathy (BSE).
6. The method according to claim 1, wherein the prion disease is variant Creutzfeldt-Jakob disease (vCJD).
7. The method according to claim 1, wherein the prion disease is iatrogenic Creutzfeldt-Jakob disease (iCJD).
8. The method according to claim 1, wherein the subject is a human.
9. A method for inducing an immune response to a prion protein, comprising:
contacting an antigen-presenting cell (APC) with a prion protein; and
contacting the APC with a CpG nucleic acid in an effective amount to induce an immune response to the prion protein.
10. The method according to claim 9, wherein the immune response is in vivo.

- 37 -

11. The method according to claim 9, wherein the APC is selected from the group consisting of: a B cell, a dendritic cell, a macrophage, and a monocyte.
12. The method according to claim 9, wherein the APC is a dendritic cell.
13. The method according to claim 9, wherein the APC expresses a Toll-like receptor (TLR) that signals in response to the CpG nucleic acid.
14. The method according to claim 13, wherein the TLR is TLR9.
15. The method according to claim 9, wherein the prion protein is prion protein:scrapie form (PrP^{Sc}).
16. The method according to claim 9, wherein the prion protein is a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}.
17. The method according to claim 9, wherein the prion protein is a derivative of PrP^{Sc} or a derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}.
18. The method according to claim 9, wherein the CpG nucleic acid is a Class B CpG nucleic acid.
19. The method according to claim 9, wherein the CpG nucleic acid is a Class A CpG nucleic acid.
20. The method according to claim 9, wherein the CpG nucleic acid is a Class C CpG nucleic acid.
21. The method according to claim 9, wherein the CpG nucleic acid is optimized for use in a species of the subject.

SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH
<120> USE OF CpG NUCLEIC ACIDS IN PRION DISEASE
<130> C01041.70038
<150> US 60/396,432
<151> 2002-07-17
<160> 19
<170> PatentIn version 3.1
<210> 1
<211> 2415
<212> DNA
<213> Homo sapiens
<400> 1
cggcgccgcg agtttctcct ctcctcacga ccgaggcaga gcagtcatta tggcgaacct 60
tggctgtgg atgctggttc tctttgtggc cacatggagt gacctgggcc tctgcaagaa 120
gcgcggaaag cctggaggat ggaacactgg gggcagccga taccggggc agggcagccc 180
tggaggcaac cgctacccac ctcagggcgg tggctggctgg gggcagcctc atggtggtgg 240
ctggggcag cctcatggtg gtggctgggg gcagccccat ggtggtggct ggggacagcc 300
tcatggtgt ggctgggtc aaggaggtgg cacccacagt cagtggaaaca agccgagtaa 360
gcacaaaaacc aacatgaagc acatggctgg tgctgcagca gctggggcaag tggtgggggg 420
ccttggcggc tacatgctgg gaagtgcacat gacggccat gacggccatc atcatacatt tcggcagtga 480
ctatgaggac cgttactatac gtgaaaacat gcaccgttac cccaaaccaag tgtactacag 540
gcacatggat ggtacagca accagaacaa ctttgcac gactgcgtca atatcacaat 600
caagcagcac acggtcacca caaccaccaa gggggagaac ttcaccgaga ccgacgttaa 660
gatgatggag cgcgtgggg agcagatgtg tatcacccag tacgagaggg aatctcaggc 720
ctattaccag agaggatcga gcatggtcct cttcttcctt ccacctgtga tccctctgat 780
ctctttcctc atcttcctga tagtggatg aggaaggatct tcccttttc accatcttc 840
taatctttt ccagcttgag ggaggcggta tccacctgca gcccttttag tggtgggttc 900
tcactcttc ttctctctt gtcccgata ggctaatcaa tacccttggc actgatggc 960
actggaaaac atagagtaga cctgagatgc tggtaagcc ccctttgatt gagttcatca 1020
tgagccgttgc taaatgccag gccagtaaaa gtataacagc aaataaccat tggtaatct 1080
ggacttattt ttggacttag tgcaacaggt tgaggctaaa acaaatctca gaacagtctg 1140

aaatacac~~ttt~~ gcctggatac ctctggctcc tt~~c~~agcagct agagctc~~ag~~t atactaatgc 1200
 cctatcttag tagagatttc atagctattt agagatattt tccat~~ttt~~aa gaaaacccga 1260
 caacatttct g~~c~~cagg~~ttt~~g ttaggaggcc acatgatact tattcaaaaa aatcctagag 1320
 attcttagct ct~~t~~gggatgc aggctcagcc cgctggagca tgagctctgt gtgtaccgag 1380
 aactgggg~~t~~g atgtttact tttcacagta tgggctacac agcagctgtt caacaagagt 1440
 aaatattgtc acaacactga acctctggct agaggacata ttcacagtga acataactgt 1500
 aacatata~~t~~g aaaggcttct gggacttgaa atcaa~~at~~gtt tgg~~g~~atgtt gccc~~t~~ggag 1560
 gcaac~~c~~ccccc at~~t~~tagatg tt~~t~~aaaggac cctat~~at~~gtg gcattc~~c~~ttt ctt~~t~~aaacta 1620
 taggt~~a~~atta aggcagctga aaagtaaatt gc~~c~~ttctaga cactgaaggc aaatctc~~c~~tt 1680
 tgtccattt~~a~~ cctggaaacc agaatgattt tgacata~~c~~ag gagagctgca gttgtgaaag 1740
 caccatcatc atagaggatg atgtaattt~~a~~aaaatggtca gtgtg~~c~~aaag aaaagaactg 1800
 ct~~t~~gcattt~~c~~ tttat~~t~~tctg tctcataatt gtcaaaaacc agaatttagt caagttcata 1860
 gtttctgt~~a~~ ttggcttt~~t~~g aatcaaagaa tagggagaca atctaaaaaa tatcttaggt 1920
 tggagatgac agaaat~~a~~tga ttgattt~~g~~aa gtggaaaaag aaattctgtt aatgttaatt 1980
 aaagtaaaat tattccctga attgttt~~g~~at attgtcac~~c~~t agcagat~~a~~t~~g~~ tattacttt 2040
 ctgcaatgtt attattggct tgcacttt~~g~~t g~~a~~gtatctat gtaaaaat~~a~~t atatgtat~~a~~t 2100
 aaaatata~~t~~ttgcata~~g~~ga cagacttagg agttt~~g~~ttt agagcag~~t~~ta acatctgaag 2160
 tgtcta~~a~~atgc attaactttt gtaagg~~t~~act gaatacttaa tatgtggaa accctttgc 2220
 gtgg~~t~~cctt~~a~~ ggcttacaat gtgcactgaa tcg~~t~~tc~~a~~tg taagaatcca aagtggacac 2280
 cattaacagg tctttgaaat atgc~~a~~tgtac tttat~~t~~ttt ctatattt~~g~~t aactttgcat 2340
 gttctt~~g~~ttt tg~~t~~atataa aaaaattgt~~a~~ aatgttaat atctgactga aattaaacga 2400
 gcgaagatga gcacc 2415

<210> 2
 <211> 2446
 <212> DNA
 <213> Mustela sp.

<400> 2
 tcattttgtt ttg~~t~~ttt~~g~~tt ttg~~t~~ttgcag ataagccatc atggtaaaaa g~~c~~cacatagg 60
 cagctggctc ctg~~t~~ttctct ttgtggccac atggagt~~g~~ac attggcttct gcaagaagcg 120
 g~~c~~caaagc~~c~~t ggaggaggct ggaacactgg ggggagccga tacc~~c~~agg~~g~~c agggc~~a~~gtcc 180
 tggaggcaac cgctacccac cccagg~~g~~tgg tggcggctgg g~~g~~ccagcccc acgggggtgg 240

ctggggacag ccccacgggg gtggctgggg tcagccccac gggggtggct ggggacagcc 300
gcatggtggc ggtggctggg gtcaagggtgg tgggagccac ggtcagtggg gcaagccag 360
taagccaaa accaacatga agcatgtggc gggagccgca gcagccgggg cggtcggtgg 420
gggcctgggc ggctacatgc tggggagcgc catgagcagg cccctcattc attttggcaa 480
cgactatgag gaccgctact accgtgagaa catgtaccgc taccggacc aagtgtacta 540
caagccggtg gatcagtaca gcaaccagaa caacttcgtg catgactgcg tcaacatcac 600
ggtcaaggcag cacacggtga ccaccaccac caagggcgag aacttcacgg agaccgacat 660
gaagatcatg gagcgcgtgg tggagcagat gtgtgtcacc cagtaccagc gagagtccga 720
ggcttaactac cagagggggg cgagcgccat cctcttctcg cccctcccg tgatccctcct 780
catctcaactg ctcattctcc tgatagtggg atgaggatgg cttccatt ctctccatcg 840
tcttcacctt ttacagggtt ggggaggggg tgtctaccta cagccctgtt gtggtgggt 900
ctcattccctg cttctcttta tcacccatag gctaatcccc ttggccctga tggccctggg 960
aaatgttagag cagacccagg atgctattta ttcaagcccc catgtgttgg agtccttcag 1020
gggccaatgc tagtgcaggg ctgagaataa cagcaaatca tcattgggtt acctagggt 1080
gctttttgt tggtgttgc tagtgcagct gaccgaggct aaaacaattc tcaaaacagt 1140
tttcaaatac ctttcctgg aaacctctgg ctccctgc agcttagagct cagtacatta 1200
atgtcccatc ttagccgtgt cttcatagca acttggggaa gttttctcc ccactctaaa 1260
agaacgcgat tgcaattccc tgtgcaaaga acatttctgc caaatttggaa aggaggccac 1320
atgatattca ttcaaaaagc aaaactagaa accctttgtt cttggacgca agcccgccct 1380
gcttaggagca ccaaactggg gcgatggtt gcattctgcg gcgtggctt tgccggcagcc 1440
gaggtgtcca gcgtaaatat tgatgcgacg ctagacctag gcagaggatg tttgcacagg 1500
. gaatgaacat aatcaacagt gcgaaaatgc tacaaaaaat cccacactgg ggagcagtgt 1560
ccttggaggc aagttttttt cttttggga catttaaagc ccctatatgt ggcattcctt 1620
tcttcgttaa cctaaactat agataattaa ggcagttaaa aattgaactt cttccaggc 1680
cccaagagca aatctttgtt cacttacctg gaaaccagaa tgattttgac acagaggaag 1740
gtgcagctgt taaaataacc ctcattcctag aagatgtcat catggagaaa acgatccgt 1800
gacaaaaatg atcgcatttc ttcattgctg ttcgttaatt gacagaaaacc agaattatgt 1860
caagtccttag tttctataat cagttttga atcaaagaat ggaagtccat ccaaaaaaaaaa 1920
aaaagaaata ccttaggtca cccatgacag aaatacccat tcaggttaga aaaaaggaat 1980
tctgtttaact gttatattaag taaggcaaaa ttattgtccg gattgttgcg tatcatcagc 2040

tagcagataa attagcattc tgcaatgttc ccggcttgca ctgtgcgggt atttgatgtt 2100
 aaaaaaaaaatt attatatata ttgtgtatga caaacttaga agttttgct agaggagtt 2160
 acatctgata tatctaattgc accaccagtt ttgaaaggta ctaaatactt aatatgtaga 2220
 aatccttttg cgtggtcctc aggcttacac gtgcactgaa tagtttgta tgatagagcc 2280
 catgtggtct tcgaaatatg catgtacttt atatttcta tattttaac tgggcattgt 2340
 cttgtataaa aaatgtataa acattcgaac tcttgacttag aattaaacag gaactgagtg 2400
 tgtccatgt gttgcagtg acattcacca ccgcaccctg tgggg 2446

<210> 3
 <211> 810
 <212> DNA
 <213> *Mesocricetus auratus*

<400> 3
 tcgaaaatct ccctcttagt caatttcttg ctcccttagt ttcagcaatt gctttctcgc 60
 tccatttaggc aacctttcat tttctcacct tccccattat gtaacgggag caatgggttc 120
 tggaccagtc ttccattaaa gatgattttt atagtcggtg agcgccgtca gggagtgtatg 180
 acacctgggg gcgggttaaa ccgtacaatc ccttaaacca gtctggagcg gtgactcatt 240
 tccccagggga gaagtggcgc ggccattggg gagcacgacg caagccccgc cccacccagc 300
 ccggccccgc cctgctaccc ctccctgactc actgccccgc ccgtcccccc gggcggtccg 360
 agcagcagac cgagaaggca catcgagtcc actcgatcg tcggtggcag gtaagcgct 420
 tctgaaggct ggccccggga aggggtgtgg agccaggcct cggttaaggct tcggcttccc 480
 agagccaaagc ccggcttaact ccggctctcg gggcgctgag gccgcggggc tgagggttgag 540
 tctggctggg aggtgaccgc gcacccgcag ccgcgcgtct ctttgaggga ccgaacccca 600
 ggagaggcca ggagccatcc cttccctcccg agccggctc acccccagag tcgctcgaaa 660
 atggggatg gggatgggg tggcatcttt tgactgtcgt ttgctgtttt cttctctttt 720
 tgtaatagct acagcgaaca taatttacc cagggttcca ccgtggtctc gtccgtccctc 780
 ggcatctctc agtccagtagc atacccaagg 810

<210> 4
 <211> 4020
 <212> DNA
 <213> *Ovis aries*

<400> 4
 atgggtgaaaa gccacatagg cagttggatc ctggttctct ttgtggccat gtggagtgac 60

gtgggcctct	gcaagaagcg	accaaaacct	ggcggaggat	ggaacactgg	ggggagccga	120
tacccgggac	agggcagtcc	tggaggcaac	cgctatccac	ctcagggagg	gggtggctgg	180
ggtcagcccc	atggaggtgg	ctggggccaa	cctcatggag	gtggctgggg	tcagccccat	240
ggtggtggt	ggggacagcc	acatggtggt	ggaggctggg	gtcaaggtgg	tagccacagt	300
cagtggaca	agccagtaa	gccaaaaacc	aacatgaagc	atgtggcagg	agctgctgca	360
gctggagcag	tggtaggggg	ccttggtggc	tacatgctgg	gaagtgccat	gagcaggcct	420
cttatacatt	ttggcaatga	ctatgaggac	cgttactatc	gtgaaaacat	gtaccgttac	480
cccaaccaag	tgtactacag	accagtggat	cagtatagta	accagaacaa	ctttgtgcat	540
gactgtgtca	acatcacagt	caagcaacac	acagtcacca	ccaccaccaa	gggggagaac	600
ttcaccgaaa	ctgacatcaa	gataatggag	cgagtggtgg	agcaaatgtg	catcacccag	660
taccagagag	aatcccaggc	ttattaccaa	aggggggcaa	gtgtgatcct	cttttcttcc	720
cctcctgtga	tcctcctcat	cctttcctc	attttctca	tagtaggata	ggggcaacct	780
tcctgttttc	attatcttct	taatcttgc	caggtgggg	gagggagtgt	ctacctgcag	840
ccctgttagt	gtgggtgtc	atttcttgct	tctctttgt	tacctgtata	ataataccct	900
tggcgcttac	agactgtgg	aatgacaagc	agacatgaga	tgctgtttat	tcaagtccca	960
ttagctcagt	attctaattgt	cccatcttag	cagtatttt	gtagcaattt	tctcatttgc	1020
ttcaagaaca	cctgactaca	tttccctttg	ggaatagcat	ttctgccaag	tctggaaagga	1080
ggccacataa	tattcattca	aaaaaacaaa	actggaaatc	cttagttcat	agaccaggg	1140
tccacccctgt	tgagagcatg	tgtcctgtgt	ctgcagagaa	ctataaagga	tattctgcatt	1200
tttgcggtt	acatttgcag	gtaacacagc	catctattgc	atcaagaatg	gatattcatg	1260
caaccttta	cttatggca	gaggacatct	tcacaaggaa	tgaacataat	acaaaggctt	1320
ctgagactaa	aaaattccaa	catatggaaag	aggtgccctt	ggtggcagcc	ttccattttg	1380
tatgttttaag	cacccctcaag	tgatattctt	ttcttttagta	acataaaagta	tagataatta	1440
aggtaccta	attaaactac	cttctagaca	ctgagagcaa	atctgttgtt	tatctggAAC	1500
ccaggatgt	tttgacattt	cttagggatg	tgagagttgg	actgtaaaga	aagctgagtg	1560
ctgaagagtt	catgctttt	aactatagtg	ttggagaaaa	ctcttgagag	tcccttggac	1620
tgaaaggaga	tcagtcctga	atattcattt	gaaggactga	tgctgaagct	gaaactccaa	1680
tactttggtc	acctgtatgg	aagaactgaa	ggcaggaggg	atgcttagaa	agactgaagg	1740
caggaggaga	aggggacgac	agaggatgag	atggctagat	ggcatcatgg	actcaatgg	1800
catgagctta	agtaaaactcc	aggagttggc	aatggacagg	gagacctggc	gtcctgcagt	1860

ccatgggtgc gcagagtcgg acacgattga gtgactaaat tgaggtgacc cagatccaac	1920
atagagaatg cagatacataaa actcatattc atttgattga atctttcct gaaccagtgc	1980
tagtggtaaggta tataacagca tatataggtt atgtgatgaa gagatagtgt	2040
acatgaaata tgtgcatttc ttattgctg tcttataatt gtcaaaaaag aaaatttagt	2100
ccttggtttc tgtaaaattt acttgaatca aaaggaggc atttaagaa ataaattaga	2160
gatgatagaa atctgatcca ttcagagtag aaaaagaaat tccattactg ttatcaaaga	2220
aggtaaaattt attccctgaa ttgttcaata ttgtcaccta gcagatagac actattctgt	2280
actgtttta cttagtttgc ccttggta tcctatgtaa aaacatattt gcataatgaca	2340
aacttttctt gttagagcaa ttaacatctg aaccaccta tgcattacct gttttgtaa	2400
ggtaactttt gtaaggtact aaggagatgt gggtttaatc cctaggtcag gtaaatcccc	2460
tagaggaaga aatggcaacc cactccagta ttcttgcag gaaaatccag tgggcagagg	2520
agcctggcag ggtacagtct aagagcatgg ggttgcagaa agtgagacaa gacttgagct	2580
actgaacaat aaggacaata aatgctgggt cggctaaaag gttcatttgc tttttttct	2640
gtaagatggc tcttagtagta cttgtttta tcttcattcg aaacaatttt gtttagattgt	2700
atgtgacagc tcttgatca gcatgcattt gaaaaaaaaa tcacaattgg taaatttttgc	2760
tatagccatc ttactattga agatggaaga aaagaagcaa aattttcagc atatcatgct	2820
gtacttattt caagaaagat aaccaaaatg caaaaatgta tttgtgaagt gtatggagaa	2880
ggggctgcaa ctgatcaagc ttgtcaaagt agtttgcgaa gtttcgtcgt ggagatttct	2940
tattggacga tgctccacag ttggatatac cagttgaagt tgatagtgtat caaattgaga	3000
tattgagaat aatcgatgtt ataccacgcg ggagatagct gacatactca aaatatccaa	3060
atagaacctt gaaaaccatt tgcaccatct cagttatgtt aatcaatttgc atgtttgagt	3120
tccacataag caaaaaaaaaa acaacaaaaaaa aaaatacaac ctggaccata tttgcgcatt	3180
cagttctcta ctgaaatgtat tgaaaacact ttgtttttaa aaacagattt tgattaacag	3240
tgggtacgat acaataacgt agatggaaga aattgttaggg tgagcaaaaat gaaccacacc	3300
acccaaaggcc agtcttcctc taaagaagat gtgtgtatgg tgggattggaa aagtaatcct	3360
ctattatggta ttcttctgga aaacactgct cctaatttgc ccaactgaaa acagcactca	3420
acgaaaaagca tccagaattt gtcaatagaa aacataatct tccatcgatggaa taacgcaaga	3480
ctacatattt ctttgatgac ccagcatggc tggagtttctt gattcatctg ttgtattcag	3540
acgttgcattc tttggatttt ttccattttat ttcaatctac aaaattatca taatggaaaa	3600

aatttccatt ccctggaaga tgtaaaagtgc atctgaaaa tttctttgct caaaaagata 3660
 aaaagtttg tgaacacaga attatgacgt tgcctgaaaa atggcagaag gtagtggAAC 3720
 aaaagagtGA ctatgttGtt tggtaaAGtt cttagtgAAA atgaaaaATG tgtctttat 3780
 ttttatttaa acaccaaagg cacatTTAG caacccaata ctgaatctaa aggaaactct 3840
 tctgtgtttt gtccttacag tgtgcactga tagttgtat aagaatccAG agtGatattt 3900
 gaaatacgcA tgtgcttata tttttatAT ttGtaacttt gcatgtactt gttttgttt 3960
 aaaagtttat aaatatttaa tatctgacta aaattaaaca ggagctaaaa ggagtatctt 4020

<210> 5
 <211> 795
 <212> DNA
 <213> Bos taurus

<400> 5
 atggtaaaa gcccacatagg cagttggatc ctgggtctct ttgtggccat gtggagtgac 60
 gtgggcctct gcaagaagcg accaaaaacct ggaggaggat ggaacactgg ggggagccga 120
 tacccaggac agggcagtcc tggaggcaac cgttatccac ctcagggagg gggtgtggctgg 180
 ggtcagcccc atggaggtgg ctggggccag cctcatggag gtggctgggg ccagcctcat 240
 ggaggtggct ggggtcagcc ccatgggtggt ggctggggac agccacatgg tggtgaggc 300
 tggggtcaag gtggtaccca cggtaatgg aacaaaccca gtaagccaaa aaccaacatg 360
 aagcatgtgg caggagctgc tgcagctgga gcagtggtag ggggccttgg tggctacatg 420
 ctgggaagtg ccatgagcag gcctcttata cattttggca gtgactatga ggaccgttac 480
 tatacgtaaaa acatgcacccg ttaccccaac caagtgtact acaggccagt ggatcagtat 540
 agtaaccaga acaactttgt gcatgactgt gtcaacatca cagtcaagga acacacagtc 600
 accaccacca ccaaggggga gaacttcacc gaaactgaca tcaagatgat ggagcgagt 660
 gtggagcaaa tgtgcattac ccagtaccag agagaatccc aggcttatta ccaacgaggg 720
 gcaagtgtga tcctcttctc ttccccctcgtgatcctcc tcatctctt cctcatttt 780
 ctcatacgatgatgatgat 795

<210> 6
 <211> 2188
 <212> DNA
 <213> Gallus gallus

<400> 6
 gaattccctc ggcagccagc tcctccctct cgctattttat tcctttctcc cccccctacg 60
 ctggatctgg atcatctcaa gcccggcggt gacggcttct tggatcgctc atacataaaat 120

atctgtgagt cagaggaagc aaccaccgac cccaagacct caccggagc catggctagg	180
ctcctcacca cctgctgcct gctggccctg ctgctgcgg cctgcaccga cgtcgccctc	240
tccaaagaagg gcaaaggcaa acccagtggt gggggttggg ggcggggag ccatacgccag	300
cccagctacc cccgcccagcc gggctaccct cataaccag ggtaccccca taacccaggg	360
taccccccaca accctggcta tccccataac cccggctacc cccagaaccc tggctacccc	420
cataaccag gttacccagg ctggggtcaa ggctacaacc catccagcgg aggaagttac	480
cacaaccaga agccatggaa acccccaaaa accaacttca agcacgtggc gggggcagca	540
gcggcgggtg ctgtggtggg gggcttggg ggctacgcca tggggcgcgt tatgtcaggg	600
atgaactacc acttcgatag acccgatgag taccgatggt ggagtgagaa ctcggcgcgt	660
tatcccaacc gggtttacta ccgggattac agcagccccg tgccacagga cgtcttcgtg	720
gccgattgct ttaacatcac agtgactgag tacagcattg gccctgctgc caagaagaac	780
acctccgagg ctgtggcggc agcaaaccaa acggaggtgg agatggagaa caaagtggtg	840
acgaaggtga tccgcgagat gtgcgtgcag cagtacccgc agtaccgcct ggcctcggc	900
atccagctgc accctgctga cacctggctc gccgtctcc tcctccctt caccacccctt	960
tttgcatgc actgatggga tgccgtgccc cggccctgtg gcagtgagat gacatcgtgt	1020
ccccgtgccc acccatgggg tggcccttgc ctcgcgtttt gtccatctt ggtgaagatg	1080
tcccccgcgt gcctccccgc aggctctgat ttggcaaat gggagggat tttgtcctgt	1140
cctggtcgtg gcaggacggc tgctgggtgg ggagtggat gcccaaaaaa tggcattcac	1200
cacttcctcc tcctcttcc ttctgggctc gagatatggg ctcgtccagc cttattgtc	1260
cctgcaagag cgtatctgaa aatccctttt gctaacaagc agggttttac ctaatctgt	1320
tagccccagt gacagcagag cgcctttccc cagggcacac caaccccaag ctgaggtgct	1380
tggcagccac acgtccccatg gaggctgatg gttttgggg cgtcccaagc aacaccctgg	1440
gctactgagg tgcaattgtt gcttttaat ctgccaatcc caaccctacc gtgtagatag	1500
gaactgcctg ctctgcattt tgcatgctgc aaacacccctc tgccgcagcg ccccaaaaat	1560
agagtgattt gggaatagtg aggctgaagc cacagcagct tgggattggg ctcatcatat	1620
caatccatga tgctttgctt ccagctgagc ctcactgccc ttttatagcc tgcccagagg	1680
aagggagcgc tgctaaatgc cccaaaagggt aacactgagc aaaagcttat ttcaatgtat	1740
gatagagaac gagtgcatct cgcacagatc agccatggga gcatcgtttgc ccatcagccc	1800
caaaaacccaa aggatgctaa aatgcagcca aaggggaaatc aagcacgcag ggaaggactt	1860

gaatcagctc aactggattg aaatggcaaa aggcatgagt agaacgaacg gcaagggat 1920
 gctggagatc cacccctgt gagcaaattg ttcatgcag ccaatggAAC tattgcttct 1980
 tgtgcttcag ttgctgctga tgtgtacata ggctgttagca tatgtaaagt tacacgtgtc 2040
 aagctgctcg caccgcgtag agctaatacg tatcatgtat gtgggcactg aatgccaccg 2100
 ttggccatac ccaaccgtcc taaacgattt tcacgtcgct gtaacttaag tggagataca 2160
 ctttcagttt attcagcaaa aggaattc 2188

<210> 7
 <211> 2097
 <212> DNA
 <213> Mus musculus

<400> 7
 aattccttca gaactgaacc atttcaaccg agctgaagca ttctgccttc ctatgtggtac 60
 cagtccaaatt taggagagcc aagcagacta tcagtcata tggcgaacct tggctactgg 120
 ctgctggccc tctttgtac tatgtggact gatgtcgcc tctgcaaaaa gcgccaaag 180
 cctggagggt ggaacacccgg tggaaagccgg tatcccgggc agggaaagccc tggaggcaac 240
 cgttaccac ctcagggtgg cacctggggg cagccccacg gtgggtggctg gggacaaccc 300
 catggggca gctggggaca acctcatggt ggtagttggg gtcagcccc tggcggtgga 360
 tggggccaag gagggggtaC ccataatcag tggaaacaagc ccagcaaacc aaaaaccaac 420
 ctcaagcatg tggcaggggc tgcggcagct gggcagtag tggggggct tgggtggctac 480
 atgctgggga gcgccgtgag caggccatg atccatggt gcaacgactg ggaggaccgc 540
 tactaccgtg aaaacatgta ccgctaccct aaccaagtgt actacaggcc agtggatcag 600
 tacagcaacc agaacaactt cgtgcacgac tgcgtcaata tcaccatcaa gcagcacacg 660
 gtcaccacca ccaccaaggg ggagaacttc accgagaccg atgtgaagat gatggagcgc 720
 gtgggtggagc agatgtgcgt caccctgatc cagaaggagt cccaggccta ttacgacggg 780
 agaagatcca gcagcacccgt gctttctcc tccctcctg tcatcctcct catctccttc 840
 ctcatcttcc tgatcgtggg atgagggagg cttctgtct tggcccttcg cattctcgtg 900
 gtctaggctg ggggagggggt tatccacctg tagctttc aattgagggtg gttctcattc 960
 ttgcttcctt gtgtccccca taggctaata cccctggcac tgatggggcc tgggaaatgt 1020
 acatgtacc agttgcgtt tgcttcaggt cccttgcgt gagtctgtca tcagccagtg 1080
 ctaacaccgg gccaataaga atataacacc aaataactgc tggctagttg gggctttgtt 1140
 ttggtctagt gaataaatac tggctatcc cctgacttgc acccagagta caaggtgaca 1200

gtgacacatg taacttagca taggcaaagg gttctacaac caaagaagcc actgtttggg 1260
 gatggcgccc tggaaaacag cctcccacct gggatagcta gagcatccac acgtggaatt 1320
 ctttcttac taacaaacga tagctgattg aaggcaacaa aaaaaaaaaa atcaaattgt 1380
 cctactgacg ttgaaagcaa acctttgttc attcccaggg cactagaatg atcttagcc 1440
 ttgcttggat tgaacttagga gatcttgaact ctgaggagag ccagccctgt aaaaagctg 1500
 gtcctcctgt gacgggaggg atggtaagg tacaaaggct agaaaacttga gtttcttcat 1560
 ttctgtctca caattatcaa aagctagaat tagcttctgc cctatgtttc tgtacttcta 1620
 tttgaactgg ataacagaga gacaatctaa acattcttctt aggctgcaga taagagaagt 1680
 aggctccatt ccaaagtggg aaagaaattc tgctagcatt gtttaatca ggcaaaattt 1740
 gttcctgaag ttgctttta ccccagcaga cataaaactgc gatagttca gcttgcactg 1800
 tggattttct gtatagaata tataaaacat aacttcaagc ttatgttcc tttttaaaac 1860
 atctgaagta tggacgccc tggcggtcc atccagttact aaatgcttac cgtgtgaccc 1920
 ttgggccttc agcgtgcact cagttccgta ggattccaaa gcagacccct agctggtctt 1980
 tgaatctgca tgtacttcac gtttctata tttgttaactt tgcatgtatt ttgtttgtc 2040
 atataaaaag tttataaaatg tttgtatca gactgacatt aaatagaagc tatgatg 2097

<210> 8
 <211> 803
 <212> DNA
 <213> Ovis aries

<400> 8
 gcagagaagt catcatggtg aaaagccaca taggcagttg gatcctgggtt ctctttgtgg 60
 ccatgtggag tgacgtgggc ctctgcaaga agcgacccaa acctggcgga ggatggaaaca 120
 ctggggggag ccgatacccg ggacaggcga gtcctggagg caaccgctat ccacccagg 180
 gaggggggtgg ctggggtcag ccccatggag gtggctgggg ccaacctcat ggaggtggct 240
 ggggtcagcc ccatggtggt ggctggggac agccacatgg tggtgaggc tgggtcaag 300
 gtggtagcca cagtcagtgg aacaagccca gtaagccaaa aaccaacatg aagcatgtgg 360
 caggagctgc tgcagctgga gcagtggtag ggggccttgg tggctacatg ctgggaagtg 420
 ccatgagcag gcctttata cattttggca atgactatga ggaccgttac tatcgtgaaa 480
 acatgtaccg ttaccccaac caagtgtact acagaccagt ggatcagtat agtaaccaga 540
 acaactttgt gcatgactgt gtcaacatca cagtcaagca acacacagtc accaccacca 600
 ccaaggggga gaacttcacc gaaactgaca tcaagataat ggagcgagtg gtggagccaa 660

tgtgcataccac ccagtaccagg agagaatccc aggcttatta ccaaagggggg gcaagtgtga 720
 tcctcttttc ttccccctct gtgatcctcc tcatctctt cctcattttt ctcatagtag 780
 gataggggca accttcctgt ttt 803

<210> 9
 <211> 765
 <212> DNA
 <213> *Rattus norvegicus*

<400> 9
 atggcgaacc ttggctactg gctgctggcc ctcttgcgtga ctacatgtac tgatgttggc 60
 ctctgcaaaa agcggccaaa gcctggaggg tggaacactg gtggaaagccg gtaccctggg 120
 cagggaaagcc ctggaggcaa ccgttaccca cctcagagtg gtggtacctg ggggcageccc 180
 catggtggtg gctggggaca acctcatggt ggtggctggg gacaacctca tggtggtggc 240
 tggggtcagc cccatggcgg gggctggagt caaggagggg gtacccataa tcagtggAAC 300
 aagcccagca agccaaaaac caacctaag catgtggcag gggctgcccgc agctggggca 360
 gtagtggggg gccttggtgg ctacatgttgg gggagtgccca tgagcaggcc catgctccat 420
 tttggcaacg actgggagga ccgctactac cgagaaaaaca tgtaccgtta ccctaaccAA 480
 gtgtactaca ggccgggtgga tcagtacagc aaccagaaca acttcgtgca cgactgtgtc 540
 aatatcacca tcaagcagca tacagtcacc accaccacca agggggagaa cttcacggag 600
 accgacgtga agatgatgga gcgtgtggtg gaggcagatgt gcgtcacccca gtatcagaag 660
 gagtcccagg cctattacga cgggagaaga tctagcgccg tgctttctc ctccccctct 720
 gtgatcctcc tcatctcctt cctcatcttc ctgatcggtt gatga 765

<210> 10
 <211> 253
 <212> PRT
 <213> *Homo sapiens*

<400> 10

Met Ala Asn Leu Gly Cys Trp Met Leu Val Leu Phe Val Ala Thr Trp
 1 5 10 15

Ser Asp Leu Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn
 20 25 30

Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg
 35 40 45

Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly
 50 55 60

Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His Gly Gly Gly
 65 70 75 80

Trp Gly Gln Pro His Gly Gly Trp Gly Gln Gly Gly Gly Thr His
 85 90 95

Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met Lys His Met
 100 105 110

Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr
 115 120 125

Met Leu Gly Ser Ala Met Ser Arg Pro Ile Ile His Phe Gly Ser Asp
 130 135 140

Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln
 145 150 155 160

Val Tyr Tyr Arg Pro Met Asp Glu Tyr Ser Asn Gln Asn Asn Phe Val
 165 170 175

His Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr
 180 185 190

Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg
 195 200 205

Val Val Glu Gln Met Cys Ile Thr Gln Tyr Glu Arg Glu Ser Gln Ala
 210 215 220

Tyr Tyr Gln Arg Gly Ser Ser Met Val Leu Phe Ser Ser Pro Pro Val
 225 230 235 240

Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
 245 250

<210> 11
 <211> 263
 <212> PRT
 <213> Bos taurus

<400> 11

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly
35 40 45

Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly
50 55 60

Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly
65 70 75 80

Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly
85 90 95

Gly Gly Trp Gly Gln Gly Gly Thr His Gly Gln Trp Asn Lys Pro
100 105 110

Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly Ala Ala Ala Ala
115 120 125

Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met
130 135 140

Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr
145 150 155 160

Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val
165 170 175

Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile
180 185 190

Thr Val Lys Glu His Thr Val Thr Thr Thr Lys Gly Glu Asn Phe
195 200 205

Thr Glu Thr Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met Cys
210 215 220

Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gln Gly Ala
225 230 235 240

Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile Ser Phe
245 250 255

Leu Ile Phe Leu Ile Val Gly
260

<210> 12
<211> 264
<212> PRT
<213> Bos taurus

<400> 12

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly
35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Gly Trp Gly Gln Pro His
50 55 60

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
65 70 75 80

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
 85 90 95

Gly Gly Gly Gly Trp Gly Gln Gly Gly Thr His Gly Gln Trp Asn Lys
 100 105 110

Pro Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly Ala Ala Ala
115 120 125

Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala
130 135 140

Met Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr
 145 150 - 155 160

Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro
 165 170 175

Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn
180 185 190

Ile Thr Val Lys Glu His Thr Val Thr Thr Thr Lys Gly Glu Asn
195 200 205

Phe Thr Glu Thr Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met
210 215 220

Cys Ile Thr Gln Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg Gly
225 230 235 240

Ala Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile Ser
245 250 255

Phe Leu Ile Phe Leu Ile Val Gly
260

<210> 13

<211> 255

<212> PRT

<213> Ovis aries

<400> 13

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly
35 40 45

Asn Arg Tyr Pro Pro Gln Gly Gly Trp Gly Gln Pro His Gly
50 55 60

Gly Gly Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His Gly
65 70 75 80

Gly Ser Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Gly Gly
85 90 95

Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met Lys
100 105 110

His Val Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly
115 120 125

Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly
130 135 140

Asn Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro
145 150 155 160

Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn
165 170 175

Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val Thr
180 185 190

Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys Ile Met
195 200 205

Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg Glu Ser
210 215 220

Gln Ala Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser Pro
225 230 235 240

Pro Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
245 250 255

<210> 14
<211> 256
<212> PRT
<213> Ovis aries

<400> 14

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly
35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His
50 55 60

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
65 70 75 80

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Gly
85 90 95

Gly Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met
100 105 110

Lys His Val Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu
115 120 125

Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His Phe
130 135 140

Gly Asn Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr
145 150 155 160

Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn
165 170 175

Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val
180 185 190

Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys Ile
195 200 205

Met Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg Glu
210 215 220

Ser Gln Ala Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser
225 230 235 240

Pro Pro Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
245 250 255

<210> 15
<211> 254
<212> PRT
<213> Mus musculus

<400> 15

Met Ala Asn Leu Gly Tyr Trp Leu Leu Ala Leu Phe Val Thr Met Trp
1 5 10 15

Thr Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn
20 25 30

Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg
35 40 45

Tyr Pro Pro Gln Gly Gly Thr Trp Gly Gln Pro His Gly Gly Gly Trp
50 55 60

Gly Gln Pro His Gly Gly Ser Trp Gly Gln Pro His Gly Gly Ser Trp
65 70 75 80

Gly Gln Pro His Gly Gly Trp Gly Gln Gly Gly Gly Thr His Asn
85 90 95

Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Leu Lys His Val Ala
100 105 110

Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met
115 120 125

Leu Gly Ser Ala Met Ser Arg Pro Met Ile His Phe Gly Asn Asp Trp
130 135 140

Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro Asn Gln Val
145 150 155 160

Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His
165 170 175

Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr
180 185 190

Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg Val
195 200 205

Val Glu Gln Met Cys Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr
210 215 220

Tyr Asp Gly Arg Arg Ser Ser Ser Thr Val Leu Phe Ser Ser Pro Pro
225 230 235 240

Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
245 250

<210> 16
<211> 8
<212> PRT
<213> *Mus musculus*

<400> 16

Gly Gly Gly Trp Gly Gln Pro His
1 5

<210> 17
<211> 8
<212> PRT
<213> *Mus musculus*

<400> 17

Gly Gly Ser Trp Gly Gln Pro His
1 5

<210> 18
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 18
tccatgacgt tcctgacggtt

20

<210> 19
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 19
tcgtcggtt gtcgtttgt cgtt

24

THIS PAGE BLANK (USPTO)